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Abstract 
The effects o f different adenosine receptor subtypes were tested to see i f they 
could affect mast cell activation by altering the histamine release. Purif ied rat 
peritoneal mast cells were chosen for this study. 
Mast cells developed f rom bone marrow progenitors are commonly found in 
various tissues. Mast cells contained numerous granules w i th mediators l ike 
histamine and hence play an important role in inflammation. Mast cells can be 
activated by various secretagogues and the subsequent response can be quantified 
by measuring the level o f histamine release. 
Adenosine is widely distributed in mammals and was formed f rom adenosine 
monophosphate (AMP) or S-adenosyl homocysteine (SAH), which was mediated 
by two enzymes, 5-nucleotidase and S A H hydrolase respectively. There are four 
different adenosine receptor subtypes identified, A i , A2A, A2B and A3, all o f which 
are members o f the G protein-coupled receptors. The level o f adenosine increases 
during inflammation, therefore suggesting that adenosine may play a role in mast 
cell moderation. Adenosine had been shown to produce a potentiation effect on the 
release o f histamine f rom mast cells but the adenosine receptor subtypes involved'' 
for the potentiation effect were stil l exclusive. We hence studied the existence of 
adenosine receptor subtypes in rat peritoneal mast cells by investigating the effects 
o f adenosine receptor agonists and antagonists on histamine release. 
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I t was observed that adenosine caused a significant increase o f histamine release in 
a dose-dependent manner on rat peritoneal mast cells. Similar ly, A j agonists 
CCPA, CPA and the A3 agonist C l - M E C A showed a dose-depending potentiation 
effect on anti-IgE induced histamine release f rom rat peritoneal mast cells. 
However, the selective A2A agonist CGS21680 demonstrated an inhibi tory effect. 
The involvement o f adenosine receptor subtypes was further elucidated by 
investigating the effects o f different adenosine receptor antagonists on the mast 
cell modulating actions o f the various adenosine receptor agonists. Cells treated 
w i th either selective A i antagonist DCPCX or selective A2B antagonist MRS 1706 
did not show any change o f adenosine receptor agonist mediated enhancement o f 
anti-IgE induced histamine release. The 八2八 antagonist ZM241385 was able to 
increase the percentage potentiation, probably because the reduction o f inhibitory 
effect by 八2八 receptor. Besides, the A3 antagonist VUF5574 was showed to cause 
a decrease o f percentage potentiation induced by the agonists, probably because o f 
the reduction o f potentiation effect by A3 receptor. Hence we suggest that A2A and 
A3 receptors exist on the rat peritoneal mast cells and respectively mediate an 
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.1. Historical Background 
The history o f mast cell research began w i t h a scientist called Paul Ehrl ich. In 
1878, he discovered that anil ine dyes displayed an absolutely staining 
characteristic behaviour toward the protoplasmic deposits o f certain type o f cell. 
F rom the descriptive point o f view, Ehr l ich suggested that anil ine-posit ive cells 
should be conveniently described as granular cells o f the connective tissue. Whi le 
from the physiological standpoint, he named the cells as mast cell ( "Mastzel le") 
because they look l ike wel l - fed cells and represent a further development o f the 
f ixed cells o f connective tissue (Ehrl ich, 1878). Ehr l ich also underlined that mast 
cells gave a typical metachiomasia when reacting w i t h the aniline dyes due to the 
granular storages o f chemical substance in the protoplasm. The b inding o f the 
chemical substance to aniline dyes showed different staining: red-violet w i th 
cyanine，orange w i t h fuchsin and red w i t h dahlia and gentian. In 1879, another 
scientist Westphal indicated that a second characteristic feature o f the mast cell 
granules in many species was their solubi l i ty in water. He discovered that mast cell 
granules are soluble in water and tissues must be fixed in 50% alcohol to preserve 
them for staining in alcoholic thionine. A t the same time, Ehr l ich also came to 
recognize two types o f cells w i th basophilic, metachromatic granules: the first type 
was derived f rom or l iv ing in connective tissues (tissue mast cells); the second 
type was the counterpart o f the neutrophil polymorph and eosinophil leucocyte 
w i th its or igin in the bone marrow and habitat in the peripheral blood (blood mast 
•V 
cell, basophil or mast leucocyte) (Ehrlich, 1891; Ehr l ich et aL, 1898). Mast cells 
are being recognized as key cells for connective tissue homoeostasis, remodeling 
and repair. 
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Mast cells are granular inf lammatory cells reside w i th in organs and play a role 
during inflammation. The mast cell is recognized as an important component o f 
the body's inf lammation and immune surveillance mechanisms. It is able to 
release potent inf lammatory mediators, such as histamine, proteases, chemotactic 
factors, cytokines and metabolites o f arachidonic acid that act on the vasculature, 
smooth muscle, connective tissue, mucous glands and inf lammatory cells. Dur ing 
anaphylactic reactions to foods, insect venom, or drugs, mediators such as 
histamine and cytokines w i l l be released by mast cells suddenly and massively 
(Gall i , 1993). Mast cells not only appear to play a key role in defense system 
against bacterial infections but also interact directly w i th cells o f the adaptive 
immune system. In fact, proliferation and activation o f mast cells, inf i l trat ion wi th 
basophils at the sites o f infection and increased levels o f bacterial-specific IgE are 
often associated w i th bacterial infection. This evidence suggests the contribution 
o f IgE, mast cells, and basophils in host defense system (McNei l et aL, 2000). In 一 
addition to histamine release, mast cells are also a primary source o f cytokines and 
chemokines, such as the pro-inflammatory interleukins ( I L ) - l , IL-6 and tumour 
necrosis factor (TNP), which are massively released during inflammation. Mast 
cell proteases may contribute to alterations in basement membranes in 
inflammation in the oral cavity, such as the disruptions that allow cytotoxic 
lymphocytes to enter the, epithelium in oral lichen planus (McNei l et aL, 2000). 
Because mast cells play a pivotal role in inflammation, therapies that target mast 
、 
cell functions could have value in the treatment o f chronic inflammatory disorders 
in the oral cavity (McNei l et aL, 2000). 
1.2. Heterogeneity of mast cells 
3 
Mast cells do not represent a homogenous population. They can have different 
phenotypes and functions, even in the same tissues. In the m id 1960,s, Enerback 
started to establish the concept o f mast cell heterogeneity through a series o f 
detailed morphological and histochemical studies on the gastrointestinal tract o f 
the rat (Enerback et al., 1986). 
Rodent mast cells can be divided into two main subtypes: mucosal mast cells 
( M M C ) and connective tissue mast cells (CTMC). The two subsets differ 
functionally and can be defined by histochemical methods. Cells positive to 
safranine in the astra blue/safiranine staining sequence are classified as CTMCs, 
whi le those positive to astra blue as MMCs. C T M C are found in the peritoneal 
cavity, skin, tongue, etc. On the other hand, M M C are mostly found in the 
intestinal mucosa. M M C were relatively smaller, much more variable in shape 
contain fewer granules and lower level o f histamine as compared to CTMC. M M C 
also contain the glycosaminoglycan chondroitin sulphate which is less sulphated 
than heparin in CTMC. Heterogeneity o f neutral protease content was also found 
in rat mast cells. Rat CTMC contain the chymotrypsin-like neutral protease rat 
mast cell protease (RMCP) I and carboxypeptidase A which is an enzyme for 
cleaving C-terminal aromatic amino acids. However, rat M M C contain a different 
chymottypsin-like neutral protease RMCP I I (Galli, 1990). 
、 
Human mast cells are also classified into two types which base on the presence o f 
proteases in their granules: one population contain both tryptase and chymase 
( M C T C ) , another population contain only trypase ( M C T ) . The M C T C cells are 
dominant in the skin and the intestinal submucosa, while the MCT cells are 
dominant in the lung and the intestinal lamina propria (Nilsson et al, 1995). MCT 
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correspond most closely to M M C , whereas M C T C correspond more to C T M C . 
Another aspect o f heterogeneity in mast cell is the functional differences and it is 
easily observed f rom their response to different stimuli. In rodents, M M C is 
unresponsive to some secretagogues such as compound 48/80 which are effective 
on C T M C (Enerback et al., 1986). It was also found that cromoglycate and 
theophylline inhibited peptide-induced secretion f rom peritoneal mast cell but not 
for intestinal mast cells. In contrast, doxantrazole was effective against both types 
o f rat msat cells (Gall i , 1990). On the other hand, human skin mast cells 
significantly release histamine when stimulated w i th compound 48/80, while 
adenoidal, colonic, lung and tonsillar mast cells are relatively unresponsive (Galli, 
1990). Human skin and bronchoalveolar lavage (Schulman et a/.,1983) mast cells 
also cause significant histamine release when stimulated w i th neuropeptide 
substance P, however most other tissues mast cells have no effect (Heaney et al., 一 
1995). 
1.3. Mast cell mediators 
Mast cells produce three main classes o f mediator: preformed and granule 
associated mediators, newly synthesized mediators and cytokines (Schwartz, 
1987). The preformed and granule associated mediators involve biogenic amines, 
neutral proteases, acid hydrolases and proteoglycans. When the mast cells are 
activated, newly synthesizes mediators such as leukotrienes (LT), prostaglandins " 
(PG) or platelet-activating factor (PAF) and a variety o f cytokines are produced 
(Table 1.1) (Bienenstock et aL, 1985; Heavey et al, 1988). 
1.3.1 Preformed and granule associated mediators 
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Ehrl ich first identif ied the mast cell by its specific microscopic feature o f high 
cytoplasmic content o f granules, which was stained w i th basic aniline dyes 
metachromatic ally (Ehrlich, 1878). This unique interaction o f a histochemical 
stain w i th mast cell granules is associated w i th the highly acidic proteoglycan 
heparin in their content. In addition to heparin, a wide variety o f acid hydrolases 
and other destructive enzymes were also identif ied wi th in the secretory granules in 
both rodent and human mast cells (Schwartz et al., 1981). 
Mast cells are the major source o f histamine in the tissue. Histamine is the 
biogenic amine derived from the precursor amino acid histidine. It is synthesized 
in the Golgi apparatus o f mast cells and basophils by decarboxylation. Mast cells 
isolated f rom human lung, skin, lymphoid tissue and small intestine contain 3 to 8 
pg o f histamine per cell. In contrast, rat peritoneal mast cells contain 10 to 30 pg 
o f histamine per cell (Benyon et al., 1987; Fox et al., 1985; Schulman et al,, 1983). 一 
The effects o f histamine are mediated through three histamine subtypes receptors 
(Hi , H2 and H3). Release o f histamine after the activation o f mast cells and 
basophils contributes to the symptoms o f allergy and anaphylaxis. During allergic 
response, the exposure to antigen led to cross-linking the bound IgE antibodies in 
the mast cells and basophils. This causes the release o f chemical mediators such as 
histamine from these cells. The symptoms of allergy and anaphylaxis such as 
vasodilation, increased vascular permeability, and contraction o f the smooth 
' 4 . 
muscle are mediated through the H i receptor. (Ennis et al., 1984). R2 
receptor-mediated activities include gastric acid production, inhibit ion of 
histamine release from basophils, T cell cytotoxicity, stimulation o f T suppressor 
activity, and leukocyte chemotaxis. The inhibit ion o f histamine release from 
basophils mediated by H2 receptor is a negative feedback to balance the immune 
6 
system. These evidences supported the contribution o f mast cells during 
inf lammation (Bach et al,, 1985). 
Three unique neutral proteases have been purif ied f rom mast cells: tryptase, 
chymase and carboxypeptidase (Schechter et al., 1983; Smith et al., 1984). Neutral 
proteases are the major protein o f the secretory granules in mast cells. There is a -
difference in proteases content between different species o f mast cells. Tryptase is 
the most abundant human mast cell protease whereas chymases appear to be 
dominant in rat (Chen et al., 1993). Tryptase is present in all human mast cells, 
whi le it is in negligible quantities in other cell types, therefore, it can act as a 
marker for detecting the source o f mast cells by using specific antibodies (Craig et 
al., 1986; Walls et al., 1990). Tryptase acts l ike pancreatic trypsin which cleaves 
the peptide and ester bonds on the carboxyl side o f basic amino acids (Tanaka et 
al., 1983). Tryptase has potent biologic activities that may contribute to the 
inflammatory response and airway hyper-reactivity seen in asthma. Tryptase levels 
are elevated in the broncho alveolar lavage (BAL) f lu id from atopic asthmatics 
compared wi th nonasthmatic controls at baseline and are significantly increased 
shortly after antigen challenge in patients w i th allergic asthma (Oh et al, 2002). 
Tryptase inactivates the airway-relaxing activity o f vasoactive intestinal peptide 
which is released from airway motor nerves whereas bronchorelaxation in guinea 
pigs is blocked by enhanced degradation o f vasoactive intestinal protein (Oh et al, 
2002). ； 
Chymase is a chymotryptic serine protease and may modulate inflammatory 
processes by controlling the bioavailability of certain cytokines at sites of mast 
cell activation (Mizutani et al, 1991). Carboxypeptidase is an enzyme which 
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cleaves the x-Gly-Phe bonds and is the most recent enzymes to be localized and 
puri f ied f rom rodent and human mast cells. In rats, carboxypeptidase is 
preferentially localized to connective tissue mast cells. In humans, a similar 
distribution is found w i th co-localization o f carboxypeptidase and chymase in 
M C T C cells (Irani et al., 1991). 
Proteoglycans are macromolecules consisting o f a protein core w i th a convalently 
bonded glycosaminoglycan (GAG) side chains. Proteoglycans have a wide range 
o f biological effects from simple mechanical support functions to cell 
differentiation and proliferation, cell adhesion and moti l i ty, and tissue 
morphogenesis (Kjel len et al., 1991). Heparin and chondroitin sulfate E are 
examples o f proteoglycans. Mast cell granules are r ich in proteoglycans. Heparin 
is most abundant in rat connective mast cells. Rat peritoneal mast cell granules 
also contain 30% heparin and 70% basic proteins in a complex. Since heparin wi th 
the highly acidic property and capacity to exclude water, it binds to the other 
pre-formed mediators and packs them orderly for storage. In addition, chondroitin 
sulfate E is commonly found wi th in human mast cell granules (Stevens et al., 1988) 
(Razin et al., 1982). 
Heparin plays an important role in influencing the distribution and function o f a 
number o f proteases in mast cells. Heparin enhances the activity o f chymase by 
i 
binding to procollagenase in tissues, the procollagenase in turn activates chymase.‘ 
Moreover, it is suggested that heparin inhibits the stimulus-coupling secretion in 
mast cell on the early asthmatic reaction and on exercise-induced asthma (Gilat et 
al., 1994). 
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1.3.2 Newly synthesized mediators 
The major difference between newly synthesized mediators and preformed 
mediators is that newly synthesized mediator are not preformed but generated 
once the mast cells are activated. Prostaglandins (PG), leukotrienes (LT) and 
thromboxanes (TX) are examples o f newly synthesized mediators which are 
derived f rom arachidonic acid. The newly synthesized mediators are synthesized 
by two major enzymatic pathways (Fig 1.1): cyclooxygenase pathway and 
lipoxygenase pathway (Hoeck et al., 1993). 
Cyclooxygenase (COX) is found in two isoforms: COX-1 and COX-2. COX-1 is a 
constitutive form found in almost all cell types, whi le COX-2 is induced by 
proinflammatory cytokines, growth factor and endotoxin (Xie et al., 1991). 
Unstable intermediate prostaglandin G2 (PGG2) and prostaglandin endoperoxide 
(PGH2) synthesized by COXs are further convert to active prostaglandins like 
prostaglandin D2 (PGD2) and thromboxane A2 (TXA2) by PG synthases and 
thromboxane synthetase respectively. PGD2, PGF2a and TXA2 are powerful 
constrictor agonists on airway smooth muscle. They play a role in the early 
bronchoconstrictor responses to inhaled allergen and are believed to be largely 
mast cell-dependent. PGD2 is also a potent inhibitor for platelet aggregation 
(Hardy et al., 1984). 
Apart from COX pathway, arachidonic acid may also be metabolized by a variety. 
of lipoxygenase enzymes to yield unstable hydroperoxyeicosatetraenoic acids 
(HPETEs). The major enzyme 5-lipoxygenase metabolise the arachidonic acid to 
leukotriene A4 (LTA4) and then LTA4 may derive to LTB4 or LTC4, LTD4 and 
LTE4 by LTA4 hydrolyase and LTC4 synthase respectively. The cysteinyl 
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leukotrienes are extraordinarily potent and long acting bronchoconstrictor when 
inhaled by human. Some clinical trials showed that about 80% o f the early 
bronchoconstrictor response to inhaled allergen can be eliminated by cysteinyl 
leukotriene receptor antagonists and leukotriene synthesis inhibitors. On the other 
hand, cysteinyl leukotriene receptor antagonists and leukotriene synthesis 
inhibitors can also block 50% to 60% o f the late response to inhaled allergen 
(Findlay et aL, 1992; Rasmussen et aL, 1991). 
1.3,3 Cytokines 
Cytokines produced by mast cells include interleukin ( I L ) - l , IL-2, IL-3, IL-4, IL-5, 
IL-6, tumour-necrosis factor (TNF), granulocyte-macrophage colony-stimulating 
factor ( G M - C S F ) and interferon ( I F N ) - Y . The generation o f proinflammatory 
cytokines plays an important role in allergic inf lammation and late phase of 
allergic response. TNF-a is a key cytokine in allergic inflammation which is 
required to initiate the endothelial and epithelial adhesion molecules and 
chemokine secretion. TNP-a also increases the bronchial responsiveness to 
inhaled stimuli and promotes mediator secretion from lung mast cells. Other 
interleukins l ike IL-4 and IL-5 are important for the maturation, activation and 
survival o f eosinophils (Bradding et aL, 1994). 
1.4. Mast cell activation 
1,4.1 Aggregation of IgE Receptors (FcsRI) 
Immunoglobulin E (IgE) like all immunoglobulins consists of two disulphide 
bonded heavy chains and two light chains bound to the heavy chains. IgE 
production is mainly under the control o f T cells and IgE is produced by 
allergen-specific plasma cells. There are two main components of the immune 
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response leading to IgE production. The first consists o f the signals that favor the 
dif ferentiat ion o f naive ThO cells to a Th2 phenotype. The second comprises the 
action o f cytokines and co-stimulatory signals from Th2 cells that stimulate B cells 
switching to produce IgE antibodies. 
Bio logica l activities o f IgE are mediated through specific h igh-af f in i ty receptors 
(FcsRI) wh ich are main ly expressed on mast cells and basophils (Blank et aL, 
1989). The FcsRI has been characterized in three different species, human, rat and 
mouse. I t has been defined as a tetrameric surface glycoprotein that comprises an 
a chain, a p chain and a dimmer o f disulphide l inked y chains. The a chain has 
been shown to b ind IgE, whi le the p and y chains are involved in cell signaling and 
surface expression (Blank et aL, 1989). The FcsRI plays a central role in allergic 
diseases including asthma, allergic rhinit is, atopic dermatitis, and food and drug 
allergy. 
B ind ing o f antigen to IgE cross-links the FcsRI receptors, i t leads to the 
aggregation o f FcsRI receptors in the plane o f the plasma membrane and this 
causes the release o f chemical mediators f rom the mast cells. Aggregation o f high 
aff in i ty IgE receptors in mast cell activates intracellular signaling pathway. 
Including the phosphorylation o f protein-tyrosine kinases, activation o f 
1 I 
phospholipases, protein kinase C, and Ca mobi l izat ion (Benhamou et aL, 1992) 
(Jouvin et aL, 1995) (Daeron，1997). FcsRI engagement also activate〜 
mitogen-activated protein kinases (Baumgartner et aL, 1996). These pathways lead 
eventually to degranulation, the synthesis and release o f l ip id mediators, and the 
production and secretion o f cytokines, chemokines and growth factors by mast 
cells. 
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1,4,2 Activation of Phospholipase C 
One o f the primary targets o f the IgE/ FcsRI receptor signaling is phospholipase C 
(PLC) which catalyses the breakdown o f phosphatidylinositol 4,5-bisphhosphate 
(PIP2) to generate two second messengers: inositol-1,4,5-trisphophosphate (IP3) 
and diacylglycerol (DAG). These signaling molecules are responsible for calcium 
release f rom intracellular stores and activation o f various protein kinase C (PKC). 
PLC must be recruited to the membrane and tyrosine phosphorylated in order to 
activate. Mast cells have been shown to contain T cells adapter protein (LAT) for 
the recruitment o f PLC (Zhang et al., 1998). Once recruited to the membrane, PLC 
is exposed to activating tyrosine phosphorylation. 
I 
IP3 mobilizes Ca from intracellular storage sites, and diacylglycerol together 
w i th Ca2+ activates protein kinase C (PKC) (Jouvin et al., 1994). Diacylglycerol 
plays a role in the fusion o f granule and plasma membranes which is a late step in 
2+ 
granule secretion. Besides, both Ca and PKC appear to be required for optimal 
mast cell degranulation (Nishizumi et aL, 1997). 
2+ 
A n important init iating step for Ca release from the ER is the binding o f IP3 to IP 
receptors in the endoplasmic reticulum membrane. The increase o f intracellular 
2 I 2十 
- Ca and the presence of external Ca source are critical to induce degranulation 
(Oka et al, 2005). The released calcium ions w i l l bind to calmodulin, which^ 
contains four calcium binding sites. Ca-calmodulin complex w i l l bind to protein 
kinases, cyclic nucleotide phosphodiesterases and Ca-transport systems of plasma 
membrane and thus causing mast cell degranulation (Oka et al, 2005). 
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PKC is a serine/threonine kinase and consists o f a , P and y isozymes. PKC is 
activated through the binding o f diacylglycerol to their binding sites that are 
present in each o f the isozymes. It plays a pivotal role in intra-cellular signaling 
cascades and phosphorylating some o f the participating proteins. The PKC family 
is a ubiquitous enzyme family which catalyzes the phosphorylation o f certain 
proteins. Dur ing mast cell activation, the antigen-induced bridging o f IgE 
receptors induces the formation o f diacyl glycerol and the binding o f diacylglycerol 
to PKC induces the activation o f protein kinase C (Mazurek et al., 1987). PKC 
phosphorylate the Raf, M E K and M A P kinases. The activation o f M A P kinase 
cascade is important for cellular responses such as exocytosis and histamine 
release in mast cell activation (Mazurek et al., 1987). 
1,4.3 Activation of Adenylate cyclase 
Cyclic adenosine monophosphate (cAMP) is synthesized from ATP by adenylate 
cyclase, which is located in the cell membrane. Cyclic A M P binds to specific 
locations on the regulatory units o f protein kinase A causing the dissociation 
between the regulatory and catalytic subunits. Thus activated catalytic units 
phosphorylate proteins substrate. The level o f cAMP is related to the release of 
mediators from mast cells. In early studies, it was demonstrated that 
pharmacological agents w i th cAMP-elevating properties caused inhibit antigen 
induced mediator release from lung fragments o f primates (Assem et al., 1969). 
Besides, other studies provided evidence linJdng cAMP to inhibit ion o f the allergicv 
response. A correlation between increase in intracellular levels of cAMP and 
inhibit ion of mast cells degranulation was observed (Bourne et al., 1972). 
However, these suggestions were questioned by other scientists showing opposite 
results. Some studies showed that immunological activation of mast cells 
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produced a transient increase in the intracellular level o f cAMP (Winslow et al,, 
1982). A small percentage o f membrane adenylate cyclase is transmembrane 
l inked to IgE receptor. The cross-linking o f IgE receptor leaded the coupling o f 
IgE receptor to adenylate cyclase and thus activated the adenylate cyclase wi th 
fo l lowing a monophasic rise in cAMP during the mast cell degranulation (Swaim 
et al., 1994). Wi th in these arguments, cAMP may act as a balance between mast 
cell activation and inhibit ion. 
1.5. Adenosine 
Adenosine is a ubiquitous molecule present in every cell o f the human body. It is a 
nucleoside consisting o f adenine in glycosidic linkage wi th sugar and ribose. 
Extracellular adenosine is formed from adenosine 5 ‘-monophosphate (AMP) or 
S-adenosyl homocysteine (SAH) by a plasma membrane bound enzyme 
5'-nucleotidase and S A H hydrolase respectively. The source o f the A M P is 
probably cellular and is formed during energy production from adenosine 
5'-diphosphate (ADP) and adenosine 5'-triphosphate (ATP) (Polosa, 2002). 
Another source o f extracellular A M P come from the degradation o f extracellular 
ATP and cAMP. During high energy demand, 5'-nuleotidases actively metabolise 
intracellular A M P and convert it to adenosine to release energy (Polosa, 2002). 
- The enzyme adenosine deaminase (ADA) leads to the breakdown of adenosine to 
hypoxanthinie and inosine (Moriwaki et al., 1999). 
、 
1.5.1 Adenosine receptors 
At present there are four established adenosine receptors that have been cloned, 
they are A i , A2A, A2B and A3 receptors. A l l adenosine receptors are members of the 
G protein-coupled receptors. Adenosine and its agonists act via these receptors and 
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are able to modulate the activity o f mast cell. The different receptors have 
differential stimulatory and inhibitory effects on cells. For example increased 
intracellular concentrations o f cAMP by the A2 receptors can suppress the activity 
o f immune and inflammatory cells whereas the activation o f A i and A3 receptors 
inhibited the formation o f cAMP in the mast cells (Duf fy et al., 1995). 
A J adenosine receptors 
A l adenosine receptors have a high aff ini ty for adenosine and for adenosine 
analogues substituted at the N^ position e.g. L-N^-phenylisopropyladenosine 
(L-PIA) (Feoktistov et al,, 1997). A i receptors mediate the inhibit ion o f adenylate 
cyclase and its activation can also inhibit G protein-coupled activation o f voltage 
dependent Ca+ channels and is reported to induce phospholipase C activation 
(Polosa, 2002). A i receptor is found in adipose tissue, heart muscle, central 
nervous system and inflammatory cells such as neutrophils. But binding data 
indicate that the A i receptor is not particularly abundant in normal human lung 
(Stiles et al., 1992). In rats, the adenosine mediated antigen induced airways 
hyperreactivity was been shown to be mediated by a mechanism involving the A i 
receptor. Other studies showed that adenosine induced bronchoconstriction is 
mediated through the A i receptor in rats. In human lung, activation o f A i receptor 
increases airways hyperresponsiveness which is associated wi th lung inflammation 
(Polosa, 2002). Although some data support that the adenosine A ! receptor is a 
potential therapeutic target for allergic asthma or chronic obstructive pulmonary 
disease (COPD), there is no confirmation that this receptor subtype is involved in 
airway responses to adenosine in humans (Chunn et al., 2001). 
A2 adenosine receptors 
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In contrast to the A i receptor, A2 receptor stimulation leads to the activation of 
adenylate cyclase resulting in the increase o f intracellular cAMP. A2 receptors are 
more widely distributed than A i receptors. They are found in pre- and postsynaptic 
nerve terminals, mast cells, airway smooth muscle and circulating leukocytes 
(Olah et al., 1995). They bind to adenosine w i th less aff ini ty than A i receptors and 
are preferentially stimulated by adenosine analogues substituted at the 5'-N 
position e.g. 5'-A/'-ethylcarboxamideadenosine (NECA). 
A2 receptors are subdivided into the A2A and A2B receptors which are based on 
high and low aff ini ty to adenosine, respectively. A2A receptors are expressed in the 
central nervous system, vascular smooth muscle, endothelium and on neutrophils, 
platelets, mast cells and T cells (Polosa, 2002). The A2A receptor generally appears 
to inhibit mediator release from these immune cells. Although the A2B receptor is 
structurally similar to the A2A receptor, it is functionally very different to the A2A 
receptor. A2B receptor activates adenylate cyclase in order to potentiate the 
intracellular calcium levels. In most o f the cell types, A2A subtype inhibits 
intracellular calcium levels whereas the A2B subtype potentiates them (Feoktistov 
et al., 1997). A2B receptors were proposed to stimulate phospholipase C in mouse 
bone marrow-derived mast cells, in contrast, there is no evidence indicating 
similar activities for A2A receptors under physiological conditions. Furthermore, 
the activation of A2B receptor is coupled to Gs-proteins and the activation of the 
* 
G-protein facilitates calcium influx through cholera toxin-sensitive mechanism. 
Therefore, stimulation of A2B receptors may increase intracellular calcium through 
a mechanism involving phospholipase C activation (Feoktistov et al, 1997). The 
A2B receptor has been identified widely including the brain, human bronchial 
epithelium, endotheial cells, muscle cells, neurons, glial cells, fibroblasts and mast 
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cells (Polosa, 2002). It has also been proposed that adenosine contributes to the 
pathogenesis o f inf lammatory airways disease by acting on the mast cells A2B 
receptor to enhance the release o f pro-inflammatory mediators (Polosa, 2002). 
As w i th the A i receptor, stimulation o f A3 adenosine receptor leads to inhibit ion o f 
adenylate cyclase. It has also been shown to stimulate—directly phospholipase C 
and D. Experiments in HL-60 promyeloid leukaemia cells have shown that A3 
receptor activation results in the inf lux o f calcium and its release from intracellular 
stores (Jacobson, 1998). The A3 receptor is distributed widely and is found in the 
kidney, testis, lung, mast cells, eosinophils, neutrophils, the heart and brain cortex 
(Polosa, 2002). A3 receptor mediated degranulation o f mast cells or enhancement 
o f allergen induced mast cell degranulation and is believed to play a role in animal 
models o f allergic responses. However, the A3 receptor is not present on human 
lung mast cells. The presence o f A3 receptors in human eosinophils and 
macrophages suggests other mechanisms for the involvement o f A3 receptors in 
inflammatory conditions including asthma (Walker et al,, 1997). 
1.5.2 Selective agonists and antagonists 
Due to its susceptibility to extensive metabolism, endogenous adenosine is not 
suitable for characterizing the effects o f individual adenosine receptor subtypes. 
Therefore some adenosine derivatives are developed for further investigating the 
adenosine receptors. A l l o f the known adenosine receptor agonists are closely^ 
related to adenosine in structure wi t l i few modifications. Adenosine is the 
structural core o f all agonists known to date. There are three possible positions in 
adenosine may be modified to increase aff inity to specific receptor subtypes 
without destroying the agonistic activity. The positions are the 5'-position of the 
17 
nbose’ the 2- and N -^posU.ons of the punne (Fig 1 -2) (Klotz, 2000). 
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selective agonist which was 140 fold selective as compared wi th A i receptors in 
rat models (Hutchinson, 1989). Substitution o f the 2-position o f N E C A wi th 
alkynyl chains results in a decrease o f A i aff ini ty and a concomitant increase o f 
the potency at A2A receptors (Cristalli et aL, 1992). Unfortunately, no A2B specific 
agonist has been currently developed. 
Two groups o f selective adenosine receptor antagonists were developed: xanthine 
derivatives and non-xanthine derivatives. The xanthine derivatives and their 
modifications constitute a potential group o f adenosine receptor antagonists. The 
most important site o f the xanthine structure that allows for the variation is the 
8-position (Fig 1.4). It have been shown that the 8-position substitution increase 
the antagonist potency. DPCPX (8-cyclopentyl-l,3-dipropylxanthine) is an 
example o f 8-position modification and was the prototypical Ai-selective 
antagonist w i th a 1000-fold higher potency at rat A i subtype compared to the rat 
A2A receptor (Fig 1.4)(Bmns et aL, 1987). A n interesting f inding showed that a 
series o f 3-methyl-1-propargyl-xanthines in combination wi th a 7-methyl-8-styryl 
substitution display A2A selectivity (Saner et al., 2000) (Sauer et aL, 2000). The 
first non-xanthine adenosine receptor antagonist identified was the 
triazoloquinazoline CGS15943 (5-amino-9-chloro-2-(2-fliryl)[ 1,2,4]triazolo[ 1,5-
c]quinazoline). CGS 15943 is a nonselective antagonist w i th Ki-values in the low 
nanomolar range for A ! and A2A receptors and approximately 10 fold lower 
-V 
potency at the A2B and A3 subtypes (Klotz et al., 1998). Modif ication of the 
molecule led to the development o f an A2A selective compound ZM241385 
(4-[2-[7-amino-2-(2-furyl)[l，2,4]triazolo[2,3-a]triazin-5-ylamino]-ethyl]phenol). 
Structural elements of both CGS 15943 and ZM241385 are found in another 
non-xanthine compound wi th the code SCH 58261 (7-(2-phenylethyl)-
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5-amino-2-(2-f l i ry l )pyrazolo[4,3-e] [ l ,2,4] t r iazolo[ l ,5-c]pyr imidine wh ich is a A2A 
antagonist. However, the antagonists listed only represent a l imi ted selection. A 
large number o f compounds have been developed over the years. MRS 1523, 
VUF5574 and VUF8504 are examples o f new antagonist. 
1.5.3 Physiological and pathological roles of adenosine 
Adenosine has been suggested to play a role in inf lammatory airway diseases such 
as asthma and chronic obstructive pulmonary disease (COPD). Increased levels o f 
adenosine have been measured in the airway lavage f lu id o f patients w i t h asthma 
and COPD when compared to the normal patients (Driver et al., 1993). In 
sensitized rabbit experiments, high concentrations o f adenosine have been reported 
in the lung-lavage f lu id after allergen challenge (A l i et al., 1994). In transgenic 
mice studies, adenosine receptor transcripts are increased in association w i th lung 
inf lammation and increased airways hyperresponsiveness (Chunn et al., 2001). 
Inhalation o f adenosine was showed to elicit concentration-related 
bronchoconstriction in subjects w i th asthma and COPD (Oosterhoff et al., 1993). 
Further evidence l ink ing adenosine signaling to asthma and COPD is provided by 
the f inding that many cell types that play important roles in the exacerbation o f 
these conditions，express adenosine receptors and demonstrate relevant effects 
through stimulation o f these receptors. These include mast cells, eosinophils, 
lymphocytes, neutrophils and macrophages. When A M P was directly instil led into 
asthmatic bronchi or into the nose o f patients w i th allergic rhinitis, significant v 
increases in the concentration o f histamine and tryptase were detected in their 
lavage f lu id (Polosa et al., 1999). Hence, it was suggesting the important 
contribution o f airway mast cells. 
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Recently, adenosine has been used cl inical ly as an antiarrhythmic agent for the 
short-term management or diagnosis o f specific supraventricular and ventricular 
arrhythmias. Adenosine triggers synthesis and release o f prostaglandins, whereas it 
exerts pronounced negative chronotropic and dromotropic actions on cardiac 
pacemakers and atrioventricular nodal (AV) conduction respectively. Although 
adenosine's efficacy in the short-term treatment o f supraventricular disorders is 
wel l established, observations in experimental models indicated that it also could 
have a beneficial effect in certain types o f ventricular arrhythmias. Intravenous 
adenosine significantly suppressed the frequency and severity o f early ischemic 
arrhythmias in rats subjected to left anterior descending coronary artery ligation 
(Fagbemi et al., 1984). In dog experiments, adenosine infused into the lumen of 
the left ventricle reduced both the number o f extrasystoles that occurred during the 
first 30 minutes after coronary artery occlusion and the frequency o f ventricular 
f ibr i l lat ion on reperfusion o f an ischemic zone (Wainwright et al., 1988). 
Adenosine has long been recognized to be involved in the autoregulation of 
cerebral blood f low (Winn et al., 1981). When adenosine applied externally to 
cerebral blood vessels induces vasodilation and there is an evidence that 
endogenous adenosine is a tonic regulator o f vascular smooth muscle tone. 
Adenosine modulates vascular resistance through the activation of A2A adenosine 
receptor (Phillis, 1989) (Phillis 1989). Thus, application o f adenosine antagonists 
•k 
causes vasoconstriction and reverse adenosine mediated vasodilation (Hylland et 
al,, 1994). 
1.6. Role of adenosine receptors in mast cell activation 
Adenosine modulates many physiological processes, one o f the processes is mast 
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cell activation. Adenosine showed various effects at different sources o f mast cell 
such as rat peritoneal cavity, mouse bone marrow or human lung (Cooper et al, 
1978). The effects o f adenosine are mediated through the four receptors (A i , A2A, 
A2B and A3), therefore, many scientists started to investigate the relationship 
between adenosine receptors and mast cell activation at different mast cells. 
Research in the early 1980s showed that histamine release was inhibited by 
pre-incubating human mast cells w i th adenosine. In different concentration o f 
adenosine, it sometimes showed a small potentiation and sometimes showed a 
great inhibi t ion (Schleimer et al., 1982). A t that time, people did not clearly 
understand the effects o f different adenosine receptors and they thought that both 
the inhibit ion and potentiation o f histamine release were due to the activation o f 
A2 receptor only. However, other study had showed that activation o f A2 receptor 
inhibited histamine release (Hughes et al., 1984). In this study human lung mast 
cells were preincubated wi th adenosine, NECA, L -P IA or D -P IA before the 
challenge o f anti-IgE. The results showed an inhibit ion o f histamine release o f 
mast cells and the rank order o f inhibitory potencies was N E C A » adenosine 
>L -P IA > D-PIA. These results indicated that the inhibit ion o f histamine release 
through the interaction w i th A2 adenosine subtypes. 
In the early 1990s, a new adenosine receptor, the A3 receptor was cloned from rat 
tissues (Meyerhof et al., 1993). Afterward, human, sheep and rabbit A3 adenosine 
receptors have been cloned. In 1997, Reeves et al proved that adenosine A3 
receptors promoted mast cell degranulation of rat mast cells both in vitro and in 
vivo. In rat isolated pleural mast cells, the A3 agonist ( IB-MECA) induced 5-HT 
release both in vitro and in vivo and the adenosine A1/A2 antagonist, 
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8-phenyltheophyl l ine (8-PT) had no effect on the response to I B - M E C A (Reeves 
et al., 1997). Another similar study also showed that A3 adenosine receptor plays a 
role in mast cell degranulation. Dexter EJ showed that the I B - M E C A potentiated 
immunologic histamine release f rom rat and mouse peritoneal mast cells i n a dose 
response manner and the dose-response curve for I B - M E C A was less affected by 
8-PT, the A l antagonist (DPCPX) and the A2 antagonist (CGS15943). Mechanistic 
studies showed augmented histamine release was coupled w i t h a parapllel rise in 
IP3 production, indicating the activation o f A3 receptors. The agonists both induced 
histamine release and potentiated secretagogues induced release f rom mouse 
peritoneal mast cells w i t h first effect probably the result o f A3 receptor activation, 
and the second due to stimulation o f either A2B or A3 receptors (Dexter et al,, 
1999). A n opposite result showed that the degranulation is mediated by A2B 
receptor rather than A3 receptor (Butchers et al., 1999). In canine mast cells which 
it contained A i ’ A2B and A3 receptors, degranulation seems to be mediated 
pr imar i ly by A2B receptor stimulated by the non-specific agonist (NECA) but not 
by the A3 selective agonist ( IB -MECA) . NECA-st imulated degranulation is 
blocked by enprofylline，an antiasthmatic xanthine w i t h low aff ini ty for A i , A2A 
and A3 receptors. The contradictive results attracted more and more scientists to 
study the effect o f adenosine receptors in different phenotypes. 
1.7. Aim of the study 
Although there are abundant studies showing that adenosine can produce an 
enhancing effect on the release o f histamine in rat mast cells, the adenosine 
receptor subtypes involved have not been properly characterized 
pharmacologically. We hence pharmacologically characterize adenosine receptor 
subtypes existing in rat peritoneal mast cells. The effects o f selective agonists o f 
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adenosine subtypes were tested to see i f they could affect mast cell activation as 
demonstrated by altering histamine release. The adenosine receptor subtypes were 
flirther characterized w i th different adenosine receptor antagonists. 
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Main classes of mediator that are released by mast cells 
Biogenic amine 
Histamine 
Preformed and 、了 , 
granule associated N e u r a l proteases 
mediators 丄ryptase, Chymase and Carboxypeptidase 
Proteoglycans 
Heparin and Chondroit in sulfate E 
Cyclooxygenase products 
New ly synthesized PGD2，PGF^a and TXA2 
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Fig 1.2 Structure of adenosine. The position of the adenosine molecule 
that are available for modification to change receptor affinity and 
selectivity are marked with arrows (a) A^-position (b) 
2-position (c) 5'-modification. 
、 
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Fig 1.3 Structure of adenosine receptor agonists 
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Fig 1.4 Structure of adenosine receptor antagonists 
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Chapter 2 




The fo l lowing compounds and materials were used in this study. Abbreviations used 
in later chapters are listed in brackets. 
2.1.1 Mast cells secretagogues 
Supplier 
Sheep Anti-Rat IgE (Ant i- IgE) MP Biomedicals 
Compund 48/80 Sigma Chemicals 
Calcium ionophore A23187 Sigma Chemicals 
2.1.2 Anti-allergic compounds 
Theophylline Sigma Chemicals 
Disodium cromoglycate (DSCG) Sigma Chemicals 
2.1.3 Adenosine receptor agonists and antagonists 
Adenosine Sigma Chemicals 
Inosine Calbiochem 
1 -(6-Amino-9H-purin-9-yl)-1 -deoxy-N- Tocris 
ethyl-b-D-ribofuranuronamide (NECA) 
2-Chloro-N6-cyclopentyladenosine (CCPA) Tocris 
N6-Cyclopentyladenosine (CPA) Tocris 
4- [ 2 - [ [ 6 - Amino - 9 -(N- ethyl-b -D -rib o fur anuronamido syl) Tocris “ 
-9H-purin-2-yl] amino] ethyl] b enz eneprop ano i c 
acid hydrochloride (CGS21680) 
2-Phenylaminoadenosine (CV1808) Tocris 
l-[2-Chloro-6-[[(3-iodophenyl)methyl]amino] Tocris . 
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-9H-pur in-9-y l ] - l -deoxy-N-methy 
1-b-D-ribofuranuronamide (C l -MECA) 
8-Cyclopentyl- l ,3-dipropylxanthine (DPCPX) Tocris 
4-(2-[7-Amino-2-(2-f i i ryl)[ l ,2,4]tr iazolo[2,3-a] Tocris 
； l,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385) 
N-(4-Acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-l,3 Tocris 
-dipropyl-lH-purin-8-yl)phenoxy]acetamide (MRS 1706) 
N-(2-Methoxyphenyl)-N'-[2-(3-pyrindinyl) Tocris 
-4-quinazolinyl]-urea (VUP5574) 
2.1.4 Materials for buffers 
Heparin LEO Pharmaceutical 
Bovine serum albumin (BSA) Sigma 
Sodium chloride (NaCl) Sigma 
N-2-hydroxyethylpiperazine-N' -2 Sigma 
ethanesuphonic acid (HEPES) 
D-(+)-Glucose B D H 
Potassium chloride (KCl) Merck 
Sodium dihydrogen orthophosphate (NaEbPO*) B D H 
Calcium chloride (CaCl�） Sigma 
、 
2.1.5 Materials for rat sensitization 
Aluminium hydroxide (A1(0H3)) Merck 
Adsorbed diphtheria, tetanus and pertussis toxin Aventis Pasteur 
Chicken egg albumin Grade V (OVA) ICN Biomedicals -
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Inc. 
2.1.6 Materials for histamine assay 
0-phthaldialdehyde (OPT) Sigma Chemicals 
Sodium hydroxide (NaOH) B D H 
Hydrochloric acid (HCl) Mal l inckrodt 
Perchloric acid 70% Mal l inckrodt 
Methanol Mal l inckrodt 
Butanol Mal l inckrodt 
Heptane Mal l inckrodt 
B i j i 35 solution Sigma Chemicals 
Sulphuric acid Mal l inckrodt 
Dist i l led water Dept.of 
Pharmaco,CUHK 
2.1.7 Miscellaneous 
Percoll Sigma Chemicals 
Ethanol Merck 
Alcian Blue B D H 
Dimethylsulphoxide (DMSO) Sigma Chemicals 
Polystyrene disposable tubes Sarstedt 
Polystyrene disposable cuvettes Sarstedt 、 
Eppendrof tubes Sarstedt 
Pasteur pipettes Elkay 
Cover glass Chance Propper Ltd. 
Scintillation vials Wheaton 
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2.2. Buffers and stock solutions 
2.2.1 Buffer ingredients 
The chemicals for different buffers are listed below and they were dissolved in 
disti l led water. The p H o f the buffers was adjusted to 7.4 by using NaOH. 
Ingredients 
(1)HEPES buffered Tyrode 137mM NaCl, 2 .7mM KCl , 
(HEPES buffer) 0 .4mM NaH2P04.2H20, 
I m M CaCl2,10mM HEPES, 5.6mM 
Glucose 
(2)1 Ox Calcium free-HEPES buffer 10 x concentrations o f all constituents 
in HEPES buffer but omitt ing CaCl] 
(3)Heparinised buffer HEPES buffer wi th 0.1ml heparin 
added per 50ml 
(4)BSA-HEPES buffer HEPES buffer wi th Img/ml bovine 
serum albumin (BSA) was added 
(5)Calcium free-HEPES buffer HEPES buffer wi th the omission of, 
— CaCl2 
2.2.2 Stock solutions 
Anti-rat IgE was obtained in lyophilized form. It was solubilised in distilled water 
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(2ml). Calc ium ionophore A23187 was dissolved in 100% D M S O and aliquoted at a 
stock concentration o f 2 m M (40^1). It was stored at -20°C unt i l required. Compound 
48/80 was dissolved as a I m g / m l stock solution in buffer. This stock was kept at 4°C 
for two weeks. 
2.3. Source of mast cells 
2.3.1 Animals 
Rat peritoneal mast cells were obtained f rom male Sprague Dawley rats wh ich were 
supplied by the Laboratory An ima l Services Centre (LASEC) o f the Chinese 
Universi ty o f Hong Kong. 
2.3.2 Sensitization of animals 
The rats (body weight 130-180g) were sensitized w i th a 0.8ml intraperitoneal 
injection o f a mixture containing 25mg ovalbumin，2.5g A1(0H)3 and 5ml Pertussis 
tox in in 12.5ml PBS (O.OIM). The injection solution was mixed throughoutly by 
continuous stirring for at least hal f an hour before use. Af ter injection, the rats were 
kept in the animal house for three to six weeks for the development o f 
immunological response before use. 
2.3.3 Isolation of rat peritoneal mast cells 
The rats were anaesthetized w i th diethyl ether and sacrificed by cervical dislocation.^ 
fol lowed by exsanguinations under miming water. The skin in the peritoneal area 
was removed and 25 m l o f heparinised buffer was injected intraperitoneally. The 
abdomen was gently massaged for 2 minutes and was cut open along the midline. A 
disposable plastic Pasteur pipette was used to collect the peritoneal f lu id into the 
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polystyrene centrifuge tubes which were kept on ice. Peritoneal cells that were 
heavily contaminated w i th blood were discarded. The cells were pelleted by 
centrif l igation (192 x g, 4°C, 5 min.). 
23.4 Mast cells purification 
The cells were pelleted as above and resuspended in BSA-HEPES buffer. The mixed 
cell suspension was then washed once more by centrifligation and resuspended in 
1ml o f BSA-HEPES buffer. A percoll density gradient solution (4ml) containing 
3.6ml o f percoll and 0.4ml lOx calcium free-HEPES buffer was mixed w i th the cells. 
1ml o f BSA-HEPES buffer was carefully layered on top o f the percoll-cell 
suspension. The cells were then purif ied through the percoll density gradient by 
centrifl igation (150 x g, 4°C and 25min). After purification, the purif ied rat 
peritoneal mast cells were concentrated at the bottom o f the tube whi le other cell 
types were suspended between the percoll and the 1ml BSA-HEPES buffer layer on 
top. The supernatant was therefore aspirated, and the purif ied mast cells were 
washed once using BSA-HEPES buffer and twice in HEPES buffer by 
centrifligation (192 x g rpm, 4°C and 5 min.) to remove the remaining percoll 
particles. For those experiments in the absence o f extracellular calcium, mast cells 
were washed in calcium free HEPES solution. 
2.3.5 Cell counting 、 
Total mast cell number and purity was assessed by staining wi th alcian blue (1% 
alcain blue in 0.9% NaCl containing 0.5M HCl and 1% v/v Tween 20). A n aliquot of 
rat peritoneal mast cells were mixed wi th the dye in the ratio of 9:1 and incubated 
for 10 minutes at 37°C to allow cells to take up the dye. Only granules o f mast cells 
“ took up the dye and stained in blue colour. Stained cells were then counted in a 
36 
Neubaur haemocytometer. lOj^l o f dye loaded cells were added to the 
haemocytometer under a glass coverslip. The number o f stained cells was counted 
and calculated as fol lows: 
No. o f cells/ml = average number o f cells per square x di lut ion factor x lO^ 
A percentage o f stained cells can be calculated and mast cell puri ty was determined 
by comparing the number o f stained cells to the total number o f cells counted. 
2.4. General protocol for histamine release 
2.4.1 Histamine assay 
For investigating the effect o f spontaneous histamine release, isolated mast cells 
were resuspended in 450|j,l o f appropriate buffer and prewarmed for 10 minutes at 
37°C in water bath before the addition o f 50 j i l o f lOx secretagogues. For 
investigating the effects o f adenosine receptor, 200 j i l o f the purif ied mast cells after 
10 minutes equilibration at 37°C in HEPES buffer were added to 250 [xl o f the test 
compounds and 50 \il o f the secretagogue after the required pre-incubation time. 
After 10 minutes incubation, the reaction was terminated by the addition o f 1 m l ice 
cold buffer fol lowed by centrifugation (192 x g, 4°C and 5 min.). The supematants 
were decanted into test tubes and 1.5 m l o f distilled water was added to the cell 
pellet tubes. Cells suspensions were either boiled for 15 minutes at 80°C (manual''^ 
histamine assay) or treated wi th 70% v/v perchloric acid (automated assay) to 
release the residual histamine. The samples were stored at -20°C unti l the 
determination o f histamine contents. In order to eliminate endogenous adenosine, 1 
imit /ml o f adenosine deaminase (ADA) was pre-incubated wi th the purif ied mast 
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cells for 10 minutes before reacting w i th the test compounds. Secretagogues 
including anti-IgE, compound 48/80 and calcium ionophore A23187 were added as 
described above. 
2.4.2 Antagonists studies 
After purif ication, the cells were first pre-incubated w i th the adenosine receptor 
antagonists for 10 minutes in order to block the specific adenosine receptor. Another 
test drugs and anti-IgE were then added to the tubes for further 10 minutes 
incubation. After 10 minutes incubation, the reaction was terminated by the addition 
o f 1 m l ice cold buffer. 
2.4.3 Determination of histamine contents 
The principle o f the histamine assay was first described by Shore et al (1959). When 
histamine reacts wi th o-phthaldialdehyde (OPT) under alkaline conditions to form a 
fluorescent condensation product (Fig. 2.1). This product is stabilized by 
acidification and the fluorescence is measured using a spectrophotometer at an 
excitation wavelength o f 360nm and an emission wavelength o f 450nm. Detected 
fluorescence is directly proportional to histamine concentration in the original 
sample. 
2.4.2.1 Manual assay 
Each sample (1.5ml) was first treated wi th 200^1 of I M NaOH and was mixed using ‘ 
a vortex mixer. Then 100^1 of OPT ( Img/ml in methanol) was added to each sample 
and was immediately mixed by vortexing and allowing to react for 4 minutes. The 
reaction was terminated by the addition o f lOOjil o f 3 M HCl followed by vortexing. 
The samples were centrifuged (770 x g, 24 °C and 20 min.) and the fluorescence was 
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measured in an Hitachi F-4010 fluorescence spectrophotometer at the specified 
wavelengths mentioned before. Disposable polystyrene cuvettes were used to 
contain the sample being measured. 
4.3.2.2 Automated assay 
Some peritoneal mast cell samples containing drugs which interfered wi th the 
fluorescence detection were assayed wi th an auto analyser. The analyser chemically 
extracted histamine from the sample before the condensation reaction w i th OPT and 
hence eliminated any interference w i th the fluorescence detection. Drugs that 
interfered w i th the manual assay o f histamine include various adenosine receptor 
agonists and antagonists. Each 1.5ml sample was first treated wi th 30|i l o f 70% 
perchloric acid to free residual histamine from cell pellet tubes and to precipitate 
proteins in the sample. Af ter vortex mixing, the samples were centrifliged (770 x g， 
24 °C and 20 min.) to precipitate the protein or any cell debris. The samples were 
then assayed by a Bran+Lubbe Auto Analyer I I or Auto Analyer I I I . The brief 
mechanism for the Auto Analyer was that samples were first made alkaline and 
histamine was extracted into salt-saturated butanol. After separation o f aqueous and 
organic phase, heptane was added to make the organic phase less polar and 
histamine was then back-extracted into dilute HCl. The amine extracted was reacted 
wi th OPT under alkaline conditions and the product was stabilized by acidification. 
The fluorescence detected was recorded into the computer using software (AACE) 
which was supplied by the manufacturer. 
2,4.4 Calculation of histamine levels 
Histamine release was expressed as a percentage o f the total amount o f the amine 
originally present in the cells. 
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- o / o Histamine Release = Supernatant X 100% 
(Supernatant + Cell pellet) 
Supernatant = Histamine released into the supernatant 
Cell pellet = Histamine remained in mast cells 
In all experiments, values are corrected for the spontaneous histamine release by 
subtracting the spontaneous histamine release for all values obtained. Spontaneous 
histamine release was the background histamine released by mast cells in buffer 
alone. 
The potentiation o f histamine release was expressed in terms of the percentage 
potentiation of the histamine release induced by secretagogue. 
o/o Potentiation = Drug - Anti- IgE X 100% 
Anti- IgE 
Drug = Histamine release induced by anti-IgE in the presence of tested. 
drug 
Anti- IgE = Histamine release induced by anti-IgE alone 
2.5. Statistical analysis 
Results are expressed as means 土 SEM. Statistical analysis is performed using the 
Student's r-test and statistical significance is indicated by when p is less thanV 
0.05, ‘*，when p is less than 0.01 and when p is less than 0.001. 
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Condensation product 
Fig. 2.1 Condensation reaction of histamine and o-phthaldialdehyde 
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Chapter 3 
Effects of Adenosine, Adenosine Deaminase and Adenosine Receptor 
Agonists on Mast Cell Activation 
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3.1. Introduction 
For the pharmacological characterization o f receptors, the fundamental tools are 
specific agonists and antagonists. Since adenosine receptor consists o f four different 
subtypes, we started to evaluate the effects o f different adenosine receptor agonists 
on the immunological activation o f mast cells. First o f all, adenosine and N E C A are 
examples o f non-selective adenosine receptor agonists. K i values o f N E C A for rat 
A l , A2A and A3 adenosine receptor are 5.1nM, 9.7nM and 261nM respectively (Table 
3.1) (Klotz, 2000). CCPA and CPA are selective A i agonists which K i values for rat 
A l , A2A and A3 adenosine receptor are 0.4nM, 3900nin and 240nM respectively for 
the former and 2.3nM, 790nM and 203nM for rats A i , A2A and A3 adenosine 
receptor respectively for the latter (Klotz, 2000). The A2A agonist CGS21680 has the 
K i values o f 2600nM, 15nM and 3540nM for A i , k 认 and A3 adenosine receptor 
respectively in rats (Nekooeian et al, 1998). However, there is no commercially 
available selective agonist for A2B subtype. The A3 agonist C l -MECA has the K i 
values o f 820nM, 470nM and O.SSnM for A i , A2A and A3 adenosine receptor 
respectively in rats (Klotz, 2000). 
Adenosine deaminase (ADA) is a cytosolic enzyme involved in purine metabolism. 
It -catalyzes the irreversible deamination o f adenosine to inosine. The enzymatic 
mechanism initiates stereospecific hydroxyl group addition to the C6 position of the 
adenosine substrate to form the tetrahedral transition-state intermediate and then a:v 
final ammonia elimination to form the inosine product. Zinc dication is the key — 
player in the reaction acting as powerful electrophile and thus activates the water 
molecule to attack the substrate (Fig 3.1) (Cristalli et aL, 2001). Inosine is a weak 
activator of adenosine receptor as compared wi th endogenous adenosine. This 
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ubiquitous enzyme has been found in a wide variety o f microorganisms, plants, 
invertebrates and mammalian cells. However, despite o f a number o f studies 
performed to date, the physiological role played by adenosine deaminase in the 
different tissues is not clear. One unit o f commercially available adenosine 
deaminase is defined as the amount o f the enzyme that w i l l hydrolyze 1.0 ^imol 
adenosine per minute at 25。C，pH 7.5. However, it is di f f icul t to remove endogenous 
adenosine completely w i th adenosine deaminase. 
In this study, we attempted to investigate the effect o f adenosine, adenosine 
deaminase and adenosine receptor agonists on mast cell activation induced by 
anti-IgE. B y comparing the potency order o f different adenosine receptor agonists, 
the existence o f adenosine receptor subtypes was examined on the rat peritoneal 
mast cells. 
3.2. Materials and methods 
The materials and methods used are described in chapter 2. The HEPES buffer was 
prepared using nanopure water provided by the Pharmacology Department. The 
purif ied rat peritoneal mast cells were resuspended in HEPES buffer. The drugs 
were dissolved in DMSO which the final concentration was below 0.1% o f DMSO. 
Control studies were performed to test the effects o f a final concentration o f 0.1% 
、 
DMSO on the secretagogues induced histamine release. The results showed that 
DMSO below 0.1% concentration did not alter the secretagogue induced histamine 
release. For the histamine release experiments wi th 10 minutes incubation, 400|il o f 
purified cells were first equilibrated in HEPES buffer wi th 50|i l o f the tested drug 
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for 10 minutes at 37°C. Subsequently, 50|i l o f lOx secretagogues were added to the 
test tubes and incubated for further 10 minutes before addition o f ice cold buffer. For 
histamine release experiments without incubation, 400ml o f purif ied cells were 
equilibrated in FHB for 10 minutes at 371： before addition o f 50^1 o f the tested 
drug and 50^1 o f lOx secretagogues and further incubation for 10 minutes before 
addition o f ice cold buffer. Results are expressed as mean 士 SEM and are corrected 
for the spontaneous histamine release. Statistical analysis is performed using the 
Student's t-test. 
3.3. Results 
3.3.1. Effects of adenosine on anti-IgE induced histamine release in HEPES 
buffer 
Adenosine alone did not cause any histamine release. Significant potentiation of 
histamine release was observed at l O ^ M and higher concentrations when mast cells 
were activated simultaneously wi th anti-IgE and adenosine. The level o f histamine 
release w i th adenosine and anti-IgE was elevated from 24±3% to 34±3% at I m M of 
adenosine. Fol lowing 10 minutes preincubation, adenosine also showed a dose 
dependent enhancement o f anti-IgE induced histamine release from the 
concentration range o f l[iM to I m M . Significant potentiation o f histamine was 
observed at O. lmM and I m M as compared wi th the anti-IgE induced release alone*" 
and the level o f histamine release was increased from 28±2o/o to 42±3% at O. lmM of 
adenosine. Although not statistically significant, the anti-IgE induced histamine 
release was apparently reduced at concentration between 0.01 ju,M to I f i M (Fig 3.2) 
when cells were activated simultaneously wi th anti-IgE and adenosine. 
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To compare the level o f potentiation induced by adenosine and the other agonist, the 
results o f histamine release were recalculated into percentage potentiation which 
was related to the histamine release induced by anti-IgE alone. For without 
preincubation, adenosine showed a apparent biphasic effect on anti-IgE induced 
histamine release. Adenosine first showed a reduction o f anti-IgE induced histamine， 
release f rom INM to 1|LIM o f adenosine, the max imum level o f inhibi t ion was 
12±5% at 0.1|j.M o f adenosine. A dose dependent potentiation was observed 
fo l lowing the inhib i t ion phase f rom 10|LIM to I m M . The max imum percentage 
potentiation was 45±5% at I m M o f adenosine. In contrast, adenosine did not show 
any inhibi tory tendency at lower concentration range when the cells were 
preincubated w i th adenosine for 10 minutes. A dose dependent potentiation o f 
histamine release was observed from the concentration range o f I J U M to I m M . The 
max imum percentage potentiation was 39±2% at 100|aM (Fig 3.3). 
3.3.2, Effects of NEC A on anti-IgE induced histamine release in HEPES buffer 
N E C A alone did not cause any histamine release in mast cells. A n increase o f 
anti-IgE induced histamine release for both w i th and without preincubation was 
observed w i th N E C A from 0.l\iM to lO^M. Significant increase o f anti-IgE induced 
histamine release was observed at 10)aM as compared w i th the anti-IgE induced 
release alone for both w i th and without preincubation. — 
From concentrations l | i M to lOOjiM, the increase o f percentage potentiation was 
observed and increasing to the maximum level o f 22±2% at l u M of N E C A for wi th 
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preincubation. Similar to the observation o f w i th preincubation, N E C A showed a 
general increase o f percentage potentiation from concentration 1)LIM to lOOjiM and 
reached the maximum levels o f percentage potentiation o f 41±3o/o at 10\JM o f 
N E C A for without preincubation (Fig 3.4). 
3.3.5. Effects of CCPA on anti-IgE induced histamine release in HEPES buffer 
CCPA alone did not cause any histamine release. Dose-dependent potentiation o f 
anti-IgE induced histamine release was observed which was activated wi th or 
without preincubation o f CCPA. For without preincubation, CCPA showed 
significant potentiation o f histamine release at I J J M and l O ^ M CCPA and wi th 
maximum level o f 32±1% at l^ iM. Significant potentiation o f anti-IgE induced 
histamine release was observed at l | i M and 10|LIM for w i th 10 minutes 
preincubation and the maximum level o f histamine release was 23±3%. 
B y comparing the level o f potentiation, similar potency o f potentiation in the 
concentration range used were observed wi th or without preincubation. A general 
increase o f percentage potentiation was observed from the concentration I n M to 
I f i M o f CCPA and reached the maximum levels o f 20±2o/o and 29±3% at l ^ M for _ 
w i th and without preincubation respectively. After reaching the maximum levels, the 
level o f potentiation decreased at lOOj^M for both w i th and without preincubation. 
— ( F i g 3 .5 ) . -
3.3.4. Effects of CPA on anti-IgE induced histamine release in HEPES buffer 
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CPA alone did not cause any histamine release in mast cells. Significant potentiation 
o f anti-IgE induced histamine release was observed at I j i M and l O ^ M for without 
preincubation For w i th 10 minutes preincubation, significant potentiation o f anti-IgE 
induced histamine release was observed from l | i M to 100|aM o f CPA. 
About the percentage potentiation, CPA generally showed a lower potency o f 
potentiation than CCPA in both w i th and without incubation. For w i th 10 minutes 
preincubation, the maximum percentage potentiation was 16±3% at lOpJVI o f CPA. 
For without preincubation, it showed a lower potency o f potentiation than wi th 10 
minutes preincubation in the concentration range used and the maximum percentage 
potentiation was 15±3% at l ^ M of CPA (Fig 3.6). 
3.3.5. Effects of CGS21680 on anti-IgE induced histamine release in HEPES buff 
CGS21680 alone did not cause any histamine release. Comparing w i th other 
agonists, CGS21680 did not show a dose dependent potentiation o f anti-IgE induced 
histamine release in both wi th and without preincubation. Only at the level of 
100|aM CGS21680 for without preincubation was significantly higher than anti-IgE 
alone. 
When converted to percentage potentiation, it is obvious that unlike other adenosine, 
receptor agonists, CGS21680 did not demonstrate any potentiation and even showed 
a tendency o f inhibit ion at the lower concentration range for both wi th and without 
preincubation. For without preincubation, CGS21680 showed a percentage 
inhibit ion from the concentration of I n M to l | i M CGS21680. It only showed a 
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slight percentage potentiation f rom 10|j,M to 100|LIM and reached the max imum 
level o f 12±2% at lOO^iM o f CGS21680. Fo l lowing 10 minutes preincubation, 
CGS21680 showed a percentage inhib i t ion f rom the concentration o f I n M to lO j iM. 
It on ly showed a slight percentage potentiation at 100| iM and reached the max imum 
level 9±2% at lOOpM o f CGS21680 (Fig 3.7). 
3.3.6, Effects of Cl-MECA on anti-IgE induced histamine release in HEPES 
buffer 
C l - M E C A alone did not cause any histamine release. C l - M E C A generally showed a 
dose dependent enhancement o f anti-IgE induced histamine release f rom the 
concentration range used and there was only a slight decrease o f histamine release at 
the highest concentration o f lO j iM C l - M E C A tested for both w i th and without 
preincubation. For 10 minutes preincubation, significant potentiation o f anti-IgE 
induced histamine release were observed f rom O.Ol^M to l\iM. As similar to 10 
minutes preincubation, significant potentiation o f anti-IgE induced histamine release 
were observed f rom O .LJJ -M to 10|J,M for without preincubation. 
When the results were converted into percentage potentiation，the strong 
potentiating effects mediated by C l - M E C A were observed. C l -MECA showed 
similar trend o f potentiation potency for both w i th and without preincubation. For 
without preincubation, the maximum percentage potentiation was 80±10% at l \ i M 
o f C l -MECA. On the other hand, it showed a lower potency o f potentiation for wi th 
10 minutes preincubation than without preincubation in the concentration range used 
and the max imum percentage potentiation was 38±3% in the presence o f 0.1 juM 
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C l - M E C A (Fig 3.8). 
3 J . 7. Effects of adenosine deaminase on anti-IgE induced histamine release from 
rat peritoneal mast cells 
Mast cells may contain endogenous adenosine inside the cells wh ich may affect the 
anti-IgE induced histamine release，therefore the effects o f adenosine deaminase on 
anti-IgE induced histamine release was investigated. Puri f ied rat peritoneal mast 
cells were preincubated w i th adenosine deaminase for 10 minutes before being 
challenged by anti-IgE in HEPES buffer. The spontaneous histamine release o f rat 
peritoneal mast cells was 8±lo/o o f total cellular histamine and the anti-IgE induced 
histamine release was 38±4% in the absence o f adenosine deaminase. A dose 
dependent inhib i t ion o f anti-IgE induced histamine release by adenosine deaminase 
was observed when the concentration o f adenosine deaminase was increased from 
0.001 units to 10 units, a decrease o f anti-IgE induced histamine release from 
40±3o/o to 8±2o/o was observed (Fig 3.9). 
3.3.8. Effects of NEC A on anti-IgE induced histamine release with and without 
adenosine deaminase 
Since adenosine deaminase had a dose dependent inhibi t ion on anti-IgE induced 
• a. ，If 
histamine release in our mast cell activation and our previous agonist experiments 
were performed in the absence o f adenosine deaminase, some o f the adenosine 
agonists were tested again to confirm the previously observed effects o f the agonists 
in the presence o f adenosine deaminase. N E C A and C l -MECA were chosen for such 
study. 
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One unit adenosine deaminase is defined as the amount o f enzyme that w i l l 
hydrolyze 1.0 | imol adenosine per minute at 25°C，pH 7.5. According to the 
literatures, one unit o f adenosine deaminase was sufficient to hydrolyze the 
endogenous adenosine in mast cells (Cristall i et al., 2001; Linden, 1989), one unit o f 
adenosine deaminase was selected for the tested concentration. First o f all, effects o f 
N E C A w i th 10 minutes preincubation on anti-IgE induced histamine release wi th 
and without 1 unit adenosine deaminase was studied. Purif ied rat peritoneal mast 
cells and N E C A were preincubated for 10 minutes w i th or without adenosine 
deaminase before being challenged wi th anti-IgE in HEPES buffer. The spontaneous 
histamine release o f rat peritoneal mast cells was not significantly altered by the 
presence o f adenosine deaminase and were 14±1% and 13±1% o f total cellular 
histamine. However, the anti-IgE induced histamine release were reduced from 
40±2% to 25±3% for without and wi th adenosine deaminase treatment respectively. 
Similar trend o f anti-IgE induced histamine release potentiation were observed wi th 
and without adenosine deaminase. Significant increase o f anti-IgE induced 
histamine release was observed at l | i M and 10|aM o f N E C A for both wi th and 
without adenosine deaminase. The maximum anti-IgE induced histamine release in 
the absence o f adenosine deaminase was 52±1% at 10 \ iM, while that after 
preincubation wi th adenosine deaminase was 38±1% at 10 |LIM o f NECA (Fig 3.10). 
When the results were converted into percentage potentiation, dose dependent^ 
percentage potentiation was observed in the concentration range used for both wi th 
and without preincubation treatment. The maximum percentage potentiation 
mediated by NECA in the presence of adenosine deaminase was 63±8% at 10 j^M, 
whereas the maximum percentage potentiation without adenosine deaminase was 
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36±5% at 10 ) i M o f N E C A (Fig 3.11). 
Similar observations were observed when activated simultaneously w i t h anti-IgE 
and N E C A . In this set o f experiment, the spontaneous histamine release o f rat 
peritoneal mast cells were 13±lo/o and 13±lo/o o f total cellular histamine and the 
anti-IgE induced histamine release were 39±2% and 30±2% for wi thout and w i th 
adenosine deaminase respectively. Similar trend o f anti- IgE induced histamine 
release were observed. Significant increase o f anti-IgE induced histamine releases 
were only observed at 10|LIM o f N E C A in the absence o f adenosine deaminase. The 
max imum anti-IgE induced histamine release was increased to 51 ±3% at 10 \JiM o f 
N E C A in the absence o f adenosine deaminase, whereas the max imum anti-IgE 
induced histamine release was increased to 45+3% at 10 | i M o f N E C A in the 
presence o f adenosine deaminase (Fig 3.12). When the results were converted to 
percentage potentiation, similar dose dependent percentage potentiation in the 
N E C A concentration range test were observed w i th or wi thout preincubation o f 
adenosine deaminase. The max imum percentage potentiation mediated by N E C A in 
the presence o f adenosine deaminase was 56+10% at 10 ^ M , whi le the maximum 
percentage potentiation mediated by N E C A in the absence o f adenosine deaminase 
was 42土70/0 at 10 \iM o f NECA. According to the results on N E C A , adenosine 
deaminase increased the potency o f percentage potentiation but the trend o f induced 
histamine release or percentage potentiation was not affected (Fig 3.13). ^ 
3.3.9, Effects of Cl-MECA on anti-IgE induced histamine release with and 
without adenosine deaminase 
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The spontaneous histamine release o f rat peritoneal mast cells were 10±lo/o and 
10±lo/o o f total cellular histamine and the anti-IgE induced histamine release were 
34±2% and 13±2% for without and wi th adenosine deaminase respectively. Similar 
trend o f anti-IgE induced histamine release potentiation by C l -MECA were observed 
wi th and without adenosine deaminase. Ant i - IgE induced histamine release in the 
absence o f adenosine deaminase had a much higher potency than w i th adenosine 
deaminase. Significant increase o f anti-IgE induced histamine releases were 
observed from O.Olj iM to l\xM C l -MECA in the absence o f adenosine deaminase. 
However, significant increase o f anti-IgE induced histamine release was only not 
observed at O. lnM C l -MECA in the presence o f adenosine deaminase. The 
maximum anti-IgE induced histamine release mediated by C l -MECA was 46±2% at 
0.1 )JM in the absence o f adenosine deaminase, whi le that in the presence o f 
adenosine deaminase was 35±1% at 0.1 \iM C l -MECA (Fig 3.14). Al though similar 
trend o f dose dependent percentage potentiation in the concentration range tested 
were observed for both w i th and without adenosine deaminase, the percentage 
potentiation potency was much greater in the presence o f adenosine deaminase as 
compared without adenosine deaminase. The maximum percentage potentiation was 
225±20% at 0.1 j^M C l -MECA in the presence o f adenosine deaminase, while the 
maximum percentage potentiation mediated in the absence o f adenosine deaminase 
was 30±4% at 0.1 ^ U C l -MECA (Fig 3.15). 
Similar observations wi th adenosine deaminase were obtained when rat peritoneal 
mast cells were activated simultaneously wi th anti-IgE and Cl -MECA. The 
spontaneous histamine release of rat peritoneal mast cells were 10±lo/o and 10土 lo/o 
o f total cellular histamine and the anti-IgE induced histamine release were 24±3% 
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and 12±2% for without and wi th adenosine deaminase respectively. Similar trend of 
anti-IgE induced histamine release were observed. Significant increase o f anti-IgE 
induced histamine releases were observed f rom 0.1 ^iM to lOiuM C l -MECA for both 
w i th and without adenosine deaminase. Ant i - IgE induced histamine release in the 
presence o f adenosine deaminase had a lower potency than without adenosine 
deaminase. The maximum anti-IgE induced histamine release was 42±1% at l\iM in 
the absence o f adenosine deaminase, while that after preincubation wi th adenosine 
deaminase reached the maximum o f28±2% at l ^ i M o f C l -MECA (Fig 3.16). 
When the results were converted to percentage potentiation, similar dose dependent 
percentage potentiation was observed w i th and without adenosine deaminase. A 
higher potency o f percentage potentiation was observed at the concentration range 
from 0.1 )aM to 10|LIM C l - M E C A in the presence o f adenosine deaminase. The 
maximum percentage potentiation in the presence o f adenosine deaminase was 
157+20% at liLiM C l -MECA and 80±15% at l ^ i M C l -MECA in the absence o f 
adenosine deaminase (Fig 3.17). 
According to the results o f NECA and C l -MECA, adenosine deaminase enhances 
the potency o f percentage potentiation but without changing the tendency of 
— anti-IgE induced histamine release. Therefore, the previous results o f adenosine 
receptor agonists sti l l valuable for investigating the effects o f adenosine receptor、 
agonists. In order to eliminate the effects o f endogenous adenosine, one unit o f 
adenosine deaminase was added to the fol lowing antagonist experiments. 
3.3.10. Effects of CV1808 on anti-IgE induced histamine release in HEPES buffer 
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Since a new specific A2A adenosine receptor agonist CV1808 was commercially 
available, the effect o f CV1808 on anti-IgE induced histamine release in HEPES 
buffer was also investigated. Purified rat peritoneal mast cells and one unit o f 
adenosine deaminase were preincubated w i th mast cells for 10 minutes before being 
challenged w i th CV1808 and anti-IgE in HEPES buffer. The inhibitory potential was 
more obvious when the results were converted to percentage potentiation. CV1808 
showed a dose dependent percentage inhibit ion rather than potentiation. The 
maximum percentage inhibit ion was 28±3o/o at l]iM o f CV1808. The results o f 
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Fig 3.1 The adenosine deamination reaction o f adenosine deaminase (ADA) 
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Fig 3.2 Effects o f adenosine on anti-IgE (1/300) induced histamine release from 
RPMC. Mast cells were preincubated wi th adenosine for 0 or 10 minutes before the 
addition o f anti-IgE. Results are expressed as mean 土 SEM for n=6. Spontaneous 
histamine release was 18+1% and 17+1% o f the total cellular histamine and the 
anti-IgE induced histamine release was 24±3% and 28±2% for 0 and 10 minutes 
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Fig 3.3 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th adenosine for 0 or 10 
minutes before the addition o f anti-IgE. Results are expressed as mean 土 SEM for 
n=6. Spontaneous histamine release was 18+1% and 17±1% o f the total cellular 
histamine and the anti-IgE induced histamine release was 24±3% and 28±2% for 0 
and 10 minutes preincubation respectively. 
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Fig 3.4 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by NECA. Mast cells were preincubated w i th N E C A for 0 or 10 minutes 
before the. addition o f anti-IgE. Results are expressed as mean 士 SEM for n二 10. 
Spontaneous histamine release was 19±lo/o and 16±lo/o o f the total cellular 
histamine and the anti-IgE induced histamine release was 26+2% and 31±2o/o for 0 
and 10 minutes preincubation respectively. * = p < 0.05 N E C A mediated anti-IgE 
induced histamine release against anti-IgE induced histamine release alone. 
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Fig 3.5 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CCPA. Mast cells were preincubated w i th CCPA for 0 or 10 minutes 
before the addition o f anti-IgE. Results are expressed as mean 士 SEM for n=8. 
Spontaneous histamine release was 18±1% and 21±lo/o o f the total cellular 
histamine and the anti-IgE induced histamine release was 25±2% and 27±2o/o for 0 
and 10 minutes preincubation respectively. * = p < 0.05, * * = p < 0.01 CCPA 
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Fig 3.6 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CPA. Mast cells were preincubated w i th CPA for 0 or 10 minutes 
before the addition o f anti-IgE. Results are expressed as mean 土 SEM for n=7. 
Spontaneous histamine release was 18±1% and 23±lo/o o f the total cellular 
histamine and the anti-IgE induced histamine release was 32+2% and 32±2% for 0 
and 10 minutes preincubation respectively. * = p < 0.05, * * = p < 0.01 CPA 
mediated anti-IgE induced histamine release against anti-IgE induced histamine 
release alone. 
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Fig 3.7 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CGS21680. Mast cells were preincubated wi th CGS21680 for 0 or 10 
minutes before the addition o f anti-IgE. Results are expressed as mean 土 SEM for 
n二9. Spontaneous histamine release was 18±1% and 22+1% of the total cellular 
histamine and the anti-IgE induced histamine release was 30±2% and 32±2% for 0 
and 10 minutes preincubation respectively. * = p < 0.05 CGS21680 mediated 
anti-IgE induced histamine release against anti-IgE induced histamine release alone. 
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Fig 3.8 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by C l -MECA. Mast cells were preincubated w i th C l -MECA for 0 or 10 
minutes before the addition o f anti-IgE. Results are expressed as mean 土 SEM for ‘ 
n=7. Spontaneous histamine release was 16±1% and 18+1% o f the total cellular 
histamine and the anti-IgE induced histamine release was 25±3% and 33+2% for 0 
and 10 minutes preincubation respectively. * = p < 0.05, * * = p < 0.01, * * * = p < 
0.001 C l -MECA mediated anti-IgE induced histamine release against anti-IgE 
induced histamine release alone. 
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Fig 3.9 Effects o f adenosine deaminase (ADA) on anti-IgE (1/300) induced 
histamine release from RPMC. Mast cells were preincubated w i th A D A for 10 
minutes before the addition o f anti-IgE. Results are expressed as mean 士 SEM for 
n二8. Spontaneous histamine release was 8±lo/o o f the total cellular histamine and the 
anti-IgE induced histamine release is 38+4%. 
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Fig 3.10 Effects o f N E C A on anti-IgE (1/300) induced histamine release from 
RPMC. Mast cells were preincubated wi th 1 unit /ml adenosine deaminase or 
without adenosine deaminase for 10 minutes and then preincubated wi th NECA for 
further 10 minutes before the addition o f anti-IgE. Results are expressed as mean 土 
SEM for n=6. Spontaneous histamine release was 13±1% and 14±lo/o o f the total 
cellular histamine and the anti-IgE induced histamine release was 25±3% and 
40+2% for w i th and without adenosine deaminase preincubation respectively. * = p 
< 0 . 0 5 , * * = p < 0 . 0 1 against the anti-IgE induced histamine release. 
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Fig 3.11 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by NECA. Mast cells were preincubated w i th 1 unit /ml adenosine 
deaminase or without adenosine deaminase for 10 minutes and then preincubated 
wi th N E C A for further 10 minutes before the addition o f anti-IgE. Results are 
expressed as mean 土 SEM for n=6. Spontaneous histamine release was 13+1% and 
14±1% of the total cellular histamine and the anti-IgE induced histamine release was 
25±3% and 40±2o/o for wi th and without adenosine deaminase preincubation 
respectively. 
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Fig 3.12 Effects o f N E C A on anti-IgE (1/300) induced histamine release from 
RPMC. Mast cells were preincubated wi th 1 unit /ml adenosine deaminase or 
without adenosine deaminase for 10 minutes before the addition o f N E C A and 
anti-IgE. Results are expressed as mean 士 SEM for n=6. Spontaneous histamine 
release was 13+1% and 13±1% of the total cellular histamine and the anti-IgE 
induced histamine release was 30±3% and 39±3% for w i th and without adenosine 
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Fig 3.13 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by NECA. Mast cells were preincubated wi th 1 unit /ml adenosine 
deaminase or without adenosine deaminase for 10 minutes before the addition of 
N E C A and anti-IgE. Results are expressed as mean 土 SEM for n二6. Spontaneous 
histamine release was 13±1% and 13±1% o f the total cellular histamine and the 
anti-IgE induced histamine release was 30±3% and 39±3% for w i th and without 
adenosine deaminase preincubation respectively. 
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Fig 3.14 Effects o f C l -MECA on anti-IgE (1/300) induced histamine release from 
RPMC. Mast cells were preincubated wi th 1 unit /ml adenosine deaminase or 
without adenosine deaminase for 10 minutes and then preincubated wi th C l -MECA 
for further 10 minutes before the addition o f anti-IgE. Results are expressed as mean 
土 SEM for n=7. Spontaneous histamine release was 10±lo/o and 10±lo/o o f the total 
cellular histamine and the anti-IgE induced histamine release was 13+2% and 
34+2% for w i th and without adenosine deaminase preincubation respectively. * = p 
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Fig 3.15 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by C l -MECA. Mast cells were preincubated w i t h 1 uni t /ml adenosine 
deaminase or wi thout adenosine deaminase for 10 minutes and then preincubated 
w i t h C l - M E C A for further 10 minutes before the addition o f anti-IgE. Results are 
expressed as mean 士 SEM for n二7. Spontaneous histamine release was 10±1% and 
10±1% o f the total cellular histamine and the anti-IgE induced histamine release was 
13±2% and 34+2% for w i th and without adenosine deaminase preincubation 
respectively. 
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Fig 3.16 Effects o f C l -MECA on anti-IgE (1/300) induced histamine release from 
RPMC. Mast cells were preincubated wi th 1 unit /ml adenosine deaminase or 
without adenosine deaminase for 10 minutes before the addition o f C l -MECA and 
anti-IgE. Results are expressed as mean 士 SEM for n=7. Spontaneous histamine 
release was 10+1% and 10±1% of the total cellular histamine and the anti-IgE 
induced histamine release was 12+2% and 24±3% for w i th and without adenosine 
deaminase preincubation respectively. * 二 p < 0.05, * * = p < 0.01, * * * = P < 0.001 
against the anti-IgE induced histamine release. 
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Fig 3.17 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by C l -MECA. Mast cells were preincubated w i th 1 unit /ml adenosine 
deaminase or without adenosine deaminase for 10 minutes before the addition o f . 
C l -MECA and anti-IgE. Results are expressed as mean 士 SEM for n=7. Spontaneous 
histamine release was 10±1% and 10±1% of the total cellular histamine and the 
anti-IgE induced histamine release was 12±2% and 24+3% for w i th and without 
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Fig 3.18 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CV1808. Mast cells were preincubated w i th 1 unit /ml adenosine 
deaminase for 10 minutes before the addition o f CV1808 and anti-IgE. Results are 
expressed as mean 士 SEM for n=8. Spontaneous histamine release was 15±1% of 
the total cellular histamine and the anti-IgE induced histamine release was 29±3%. 
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F ig 3.19 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
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Fig 3.20 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 




Adenosine modulates many physiological processes including the release o f the 
histamine release from mast cells. However, its effects vary according to the mast 
cell phenotype (Marone et al., 1989). Early observations showed that adenosine 
potentiated the IgE induced histamine release in human lung mast cells (Hughes et 
al, 1984). Another results observed that adenosine enhanced histamine release from 
peritoneal mast cells o f Wistar rats and the magnitude o f the response being 
dependent on the secretagogues (Dexter et al, 1999). Moreover, i t had been 
suggested that adenosine enhanced antigen-mediated degranulation o f murine bone 
marrow-derived mast cells (Til ley et aL, 2000). However, in contrast, adenosine and 
its analogues inhibited immunologic histamine release from human lung mast cells 
and basophils (Dexter, 1999). In the current study, adenosine demonstrated an 
apparently biphasic effect on anti-IgE induced histamine release when it was added 
to mast cells simultaneously wi th anti-IgE: Inhibitory at low concentrations whereas 
potentiating at high concentrations. The inhibitory tendency disappeared i f cells -
were preincubated w i th adenosine for 10 minutes before challenged wi th anti-IgE. 
Apart f rom adenosine, the effects of adenosine receptor agonists were also studied. 
Previous studies showed that CPA, R-PIA and IB -MECA potentiated the anti-IgE 
induced histamine release from peritoneal mast cells o f Wistar rats. CPA and R-PIA 
were A i receptor agonists and IB -MECA was an A3 receptor agonist. While the A2A^ 
agonist CGS21680 did not potentiate the anti-IgE induced histamine release from 
peritoneal mast cells o f Wistar rats (Dexter et al, 1999). In the current study, similar 
results were obtained wi th the non-selective agonist NECA, A i receptor agonists 
CCPA, CPA and A3 receptor agonist C l -MECA all showed a dose-depending 
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potentiation effect on anti-IgE induced histamine release in rat peritoneal mast cells. 
In contrast, the A2 agonist CGS21680 showed an inhibi t ion effect rather than 
potentiation effect. 
I t was reported that adenosine have been estimated to bind to rat A2A receptor ( E C 5 0 
= 1 5 0 n M ) w i th a higher aff inity than A3 receptor ( E C 5 0 = 6500nM) (Yaar et al., 
2005). In the current study, adenosine demonstrated a biphasic effect on anti-IgE 
induced histamine release and this effect most possibly is due to combination actions 
o f different adenosine receptors. Wi th a higher aff ini ty for adenosine, the A2 
adenosine receptor may show a dominant inhibit ion effect than other adenosine 
receptors at the lower concentrations range o f adenosine, whereas w i th a lower 
aff ini ty for adenosine, the A3 adenosine receptor may only express a dominant 
potentiation effect than A2 receptor at the higher concentrations range o f adenosine. 
The loss o f the inhibitory tendency for the lower concentration after preincubation 
w i th adenosine for 10 minutes may be due to increased activation o f the A3 receptors 
through better equilibration wi th adenosine. Although it is possible that the loss of 
the inhibitory tendency may due to the desensitization o f A2A receptor, previous 
study showed that the short- term A2A receptor desensitization expressed in response 
to 30 minutes o f agonist treatment and the long-term desensitization require even 24 
hours agonist exposure (Palmer et al, 1997). Hence, the loss o f inhibitory tendency 
after only 10 minutes preincubation o f adenosine is mostly due to increased 、 
activation o f the A3 receptors through better equilibration wi th adenosine. 
In order to have a better understanding o f the adenosine actions, it is necessary to 
characterize the existence of adenosine receptors on rat peritoneal mast cells by 
studying a range o f adenosine receptor agonists. In our current study, most agonists 
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showed potentiating effect which were reduced at high concentration, whereas, the 
A2A agonist expressed inhibitory effect. Therefore, the reduction o f potentiating 
effect may be due to the activation o f the A2 receptors at high concentration. By 
comparing the rank order o f potency o f the agonists, we could characterize which 
adenosine receptors exist in rat peritoneal mast cells. Summarized from different 
literatures, the K i or ECsoof the agonists and the rank order o f potency derived from 
the K i values for different adenosine receptors are showed in Table 3.1 and Table 3.3. 
The rank order o f potency for A i adenosine receptor was CPA, CCPA > NECA, 
Adenosine > C l -MECA > CGS21680. The rank order o f potency for A2A adenosine 
receptor was CGS21680, N E C A > C l -MECA > Adenosine, CPA, CCPA. The rank 
order o f potency for A2B adenosine receptor was N E C A » CCPA » CGS21680. 
The rank order o f potency for A3 adenosine receptor was C l -MECA > NECA, 
Adenosine, CPA, CCPA > CGS21680 (Costanzi et al., 2003; Dexter et al., 1999; 
Klotz, 2000). In the present study, the concentration o f agonist showed 15% of 
potentiation by different agonists was showed in the Table 3.2 and Fig 3.19, 3.20. 
When the concentrations of the various agonists showed 15% o f potentiation, 
C l -MECA is about a hundred times more potent than other tested agonists in 
potentiating anti-IgE induced histamine release in rat peritoneal mast cells. The 
potency o f N E C A is similar to those CCPA and CPA, whereas adenosine is about 
five times less potent than CCPA and CPA.CGS21680 was not able to potentiate ’ 
anti-IgE induced histamine release to 15%, therefore CGS21680 is the least potent 
than other agonists. The rank order of potency for the adenosine receptor agonists in 
potentiating anti-IgE induced histamine release from SD rat peritoneal mast cell was 
C l -MECA > NECA, CCPA, CPA > Adenosine » CGS21680 (Table 3.3). This rank 
order o f potency is similar to those reported on A3 adenosine receptor, hence A3 
adenosine receptor may be the predominant adenosine receptor in rat peritoneal mast 
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cells. The potentiation effect o f adenosine receptor in SD rat peritoneal mast cell is 
more l ikely due to the activation o f A3 adenosine receptor. Moreover, there was an 
observation that most o f the agonists had a reduced potentiation at the higher 
concentration range and only A2 adenosine receptor agonist showed an inhibit ion 
effect on anti-IgE induced histamine release. Therefore, the reduced potency at high 
concentration o f the NECA, A ! and A3 receptor agonists and the inhibit ion effect o f 
the A2 receptor agonist suggested that there may also be an A2 induced inhibit ion in 
the rat peritoneal mast cells. In keeping wi th this suggestion, it is surprise that CCPA 
and CPA mediated potentiation effect on anti-IgE induced histamine release due to 
the absence o f A i receptor in our mast cells. However, i t is obvious when applying a 
dose concentration o f agonist to characterize the receptor. Each o f the adenosine 
receptors appears to have a similar genomic structure w i th a single intron inserted 
into the coding region. There is some level o f amino acid homology between 
different adenosine receptors. Agonist only binds to the adenosine receptor 
selectively at specific concentration range. When the agonist applied out of the 
specific concentration range, it w i l l become non-specific to one receptor subtype at 
all. In our current study, CCPA and CPA mediated potentiation on anti-IgE induced 
histamine release most probably due to the activation o f A3 receptor by non-specific 
binding o f CCPA and CPA. Similar observation was observed wi th CPA potentiated 
anti-IgE induced 54% histamine release at Wistar rat mast cells, although it was 
believed that Wistar rat mast cells may only exist o f A3 receptor (Dexter et al, 
- 水 
1999). 
Adenosine agonists sometimes produce side effects resulting from the prolonged 
application o f agonists in the body and are known as receptor desensitization (Dixon 
et aL, 1997). A prolonged application of adenosine or adenosine receptor agonist 
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may signif icantly reduce the receptor sensitivity. Desensitization was originally is 
defined for the adrenergic receptor as a loss o f functional response that occurred 
subsequent continuous agonist stimulation. It is normal ly associated wi th 
phosphorylation o f receptor protein fol lowed by uncoupling f rom the signal pathway. 
The effect o f a drug gradually diminishes due to desensitization when given 
continuously or repeatedly and often develops in the course o f a few minutes (Tsao 
et al., 2001). Desensitization is caused by a functional uncoupling o f receptors from 
heterotrimeric G proteins. Agonist-dependent phosphorylation o f receptors mediated 
by G protein-coupled receptor kinases (GRKs) appears to be responsible for this 
event and fo l lowing receptor interaction w i th intracellular proteins called arrestins. 
Then, GRKs are translocated to the membrane via interactions w i th Py subunits. 
GRK phosphorylation o f the receptor increases its aff inity for arrestin binding to the 
intracellular surface o f the receptor. Arrestins uncouple the receptor f rom G proteins 
and prevent further interactions (Claing et al., 2000). To address the desensitization 
o f adenosine receptor in the rat peritoneal mast cells, the anti-IgE induced histamine 
release mediated by various adenosine receptor agonists were evaluated wi th or 
without 10 minutes preincubation o f agonist. In the current study, adenosine 
demonstrated an inhibitory action at concentration below l) j .M adenosine for 
without preincubation. I f the cell preincubated wi th adenosine for 10 minutes before 
being challenged wi th anti-IgE, the inhibitory potential was not observed. On the 
other hand, there was a decrease of potentiation mediated by NECA at concentration 
above 0.1 |aM NECA after preincubation. While similar level o f percentage 
potentiation mediated by CCPA, CPA and CGS21680 were observed for wi th and 
without preincubation. As comparing wi th other agonists, C l -MECA showed a 
significant enhancement of potentiation in the absence o f preincubation. 
Summarizing the results, A3 receptor was desensitized after preincubated with 
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agonist for 10 minutes whereas A i and A ! receptor did not showed desensitization. 
Previous report also showed that rat A3 receptors desensitize w i th in few minutes o f 
agonist exposure by uncoupling from G-proteins and fo l lowing receptor 
phosphorylation by G-protein receptor kinases (Perry et al., 2000). Our study further 
agrees w i t h the previous study that A i A R desensitization normally occurs over 
periods o f several hours or even days (Perry et al., 2000). Hence, A i receptor did not 
show desensitization for only 10 minutes preincubation in our study. 
In order to investigate the effects o f adenosine and adenosine receptor agonists, it 
was necessary to deplete the endogenous adenosine in the cell. Previous report had 
showed that experimental adenosine analogs were resistant to deamination, therefore, 
adenosine analogs could be added to tissues or membranes to assess the effects o f 
adenosine receptor activation in the presence o f adenosine deaminase. However, it 
was showed that it was diff icult to remove endogenous adenosine completely 
(Linden, 1989)。Therefore, the dose-dependent o f adenosine deaminase was studied. 
In the current study, adenosine deaminase showed a general decrease o f histamine 
release induced by anti-IgE from O.Olunit/ml to lOunit/ml. Our previous results 
demonstrated that adenosine potentiates anti-IgE induced histamine release. The 
reduction o f anti-IgE induced histamine release in the presence o f adenosine 
deaminase most probably is due to the reduction o f endogenously produced 
adenosine. However, the detailed mechanism o f adenosine deaminase on rat 
peritoneal mast cell was stil l unclear. 
In the current study, the main focus was studying the effect o f adenosine and 
adenosine agonists on rat peritoneal mast cells, therefore, the major concern was i f 
there any differences between the effects o f adenosine and adenosine agonists after _ 
8 1 ^ 
adding adenosine deaminase into the cell system. The studies were performed on the 
N E C A and C l - M E C A enhanced anti-IgE induced histamine release w i th and without 
adenosine deaminase. 
In the current study, the percentage potentiation o f anti-IgE induced histamine 
release mediated by N E C A was sl ightly enhanced in the presence o f adenosine 
deaminase. However, when comparing the increase o f anti-IgE induced histamine 
release between each concentration o f N E C A , the increase o f anti-IgE histamine 
release between each concentration was similar for w i t h and without adenosine 
deaminase. Therefore, the potentiation potential mediated by N E C A was not 
enhanced in the presence o f adenosine deaminase because N E C A was more potent 
to occupy the binding site o f adenosine receptor than endogenous adenosine. A 
slight enhancement o f percentage potentiation most probably is due to decrease o f 
basal anti-IgE induced histamine release alone. On the other hand, the potentiation 
potential mediated by C l - M E C A was enhanced in the presence o f adenosine 
deaminase. There was an enhancement o f anti-IgE induced histamine release 
between each concentration o f C l -MECA as compared in the absence o f adenosine 
deaminase. The possible reason why adenosine deaminase enhanced the potentiation 
potential in A3 receptor agonist was about the binding o f endogenous adenosine. A 
previous report suggested that the existence o f endogenous adenosine may produce a 
weak binding to the adenosine receptors but without activating the receptors (Linden, 
1989). I f small fraction o f adenosine receptors were occupied by endogenous 
adenosine, exogenous adenosine or adenosine agonists that we added could not 
completely bind to every adenosine receptors. However, i f we added the adenosine 
deaminase to the cell system，the endogenous adenosine was eliminated, the 
exogenous adenosine or adenosine agonists could access to every adenosine 
82 
receptors and produced a greater response (Linden, 1989). When endogenous 
adenosine occupied some o f the binding site, C l - M E C A could not potentiate 
anti-IgE induced histamine release to a fu l l response. However, i t was important that 
the trend o f potentiation enhanced by N E C A and C l - M E C A did not change. They 
both showed a potentiation effect rather than inhibit ion. It confirmed that our results 
and conclusion are valid. Hence, the fo l lowing experiments were also added 
adenosine deaminase into the cell system in order to eliminating the endogenous 
adenosine and enhancing the effects o f adenosine tested drugs. 
3.5. Conclusion 
In accordance w i th previous observations that adenosine enhanced histamine release 
from peritoneal mast cells o f Wistar rats (Dexter et al., 1999), our results also 
suggested similar results that adenosine in general potentiates anti-IgE induced 
histamine release from rat peritoneal mast cells in HEPES buffer. Adenosine 
agonists o f A i and A3 receptors also in general potentiated anti-IgE induced 
histamine release from rat peritoneal mast cells. However, the A2A agonist had no 
significant effect. By comparing the rank order o f potency, the potentiation effects o f 
adenosine receptor in rat peritoneal mast cell was more l ikely due to the activation 
o f A3 adenosine receptor. However, the reduced potency at high concentration o f the 
A l and A3 receptor agonists and the inhibit ion effect o f the A2 receptor agonist 
suggested that there may also be an A2 induced inhibition. Hence, the involvement 
o f A2 and A3 adenosine receptors suggested that A2 and A3 adenosine receptors may 
exist on the rat peritoneal mast cells. 
On the other hand, the adenosine deaminase in general inhibited the anti-IgE 
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induced histamine release f rom rat peritoneal mast cell i n HEPES buffer. However, 
the adenosine deaminase only increased the potency o f the tested drugs and without 
affected the general trend o f potency induced by the tested drugs. Therefore, the 
previous results that without added the adenosine deaminase were st i l l valuable and 
the upcoming experiments were added w i th adenosine deaminase into the cell 
system. Obviously, further experiments are required to conf i rm the effects o f 
adenosine receptor agonists by using different antagonists and the existence o f 
















































































































































































































Agonist N Concentration (|iM) The maximum % 




Adenosine 6 73 45±5% 
NECA 10 0.31 41±3% 
CCPA 8 0.11 29±3% 
CPA 7 1.1 15±3% 
Cl-MECA 7 0.00075 80±10% 
b. 10 minutes 
pre-incubation 
Adenosine 6 0.87 39±2% 
NECA 10 0.54 22±2% 
CCPA 8 0.13 20±2% 
CPA 7 0.1 16±3% 
Cl-MECA 7 0.0035 38±3% 
Table 3.2 Comparison o f the potency o f different adenosine receptor agonist on 
anti-IgE induced histamine release in rat peritoneal mast cells 
、 
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Potency at various receptors 
二:s Cl- MECA > NECA, CCPA, CPA > Adenosine » CGS21680 
Al CPA, CCPA > NECA, Adenosine > Cl-MECA > CGS21680 
A2A CGS21680, NECA > Cl-MECA > Adenosine , CPA, CCPA 
A2b NECA » CCPA » CGS21680 
A3 Cl-MECA > NECA, Adenosine，CPA, CCPA > CGS21680 




Effects of Adenosine Receptor Antagonists on Mast Cell Activation 
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4.1. Introduction 
In order to conf i rm our derivation o f adenosine receptor subtypes involved in 
histamine release from rat peritoneal mast cells, adenosine receptor antagonists are 
used to block some o f the adenosine receptor subtypes. First o f all, DPCPX is a 
selective A i antagonist and similar to agonists, the af f in i ty o f antagonist to each 
adenosine receptor subtype can be reflected by the K i value. DPCPX has K i values 
o f 0.9nM, 450nM and 5300nM for Ai，A2A and A3 adenosine receptor respectively 
in rats (Table 4.1) (Klotz，2000). ZM241385 is an example o f A2A antagonist w i th 
K i values o f 257nM, 1.8nM, 16.5nM and 270 i iM for A i , A2A，A2B and A3 
adenosine receptor respectively in rats (Keddie et al., 1996). A2B adenosine 
receptor was only recently discovered, MRS 1706 is one o f the commercially 
available A2B adenosine receptor antagonists and the K i values are 37.6nM, 
548nM and 1.4nM for A i , A2A and A2B adenosine receptor respectively in rats 
( K i m et al., 2000). Among the various commercial ly available A3 receptor 
antagonist, the newly available VI IF5574 is both potent and selective w i th K i 
value o f 4 n M for A3 receptor which is > 2500 fold selectivity over the A ! and A2A 
adenosine receptors (Muller, 2003). 
In early 1980, scientists pointed out that theophylline inhibited histamine release 
through competitive antagonism o f adenosine receptor in human tissue mast cells 、 
(Delmich et al, 1985). Recent studies suggested that theophylline may act on the 
A2A adenosine receptor. It was reported that theophylline has an 
immunomodulatory action on neutrophil apoptosis via a mechanism of A2A 
antagonism (Agematsu et al., 2000). These studies suggested that theophylline 
may mediate its action through the A2A adenosine receptor. However, the action of 
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theophyll ine on rat peritoneal mast cells is sti l l unclear. 
In this study, we investigate the effect o f adenosine receptor antagonists on 
anti-IgE induced mast cell activation. Furthermore, the adenosine receptors 
involved in the biphasic actions o f adenosine on anti-IgE induced histamine 
release are further characterized and confirmed. 
4.2. Materials and methods 
The materials and methods used are described in chapter 2. For the histamine 
release experiments w i th 10 minutes incubation w i th agonists, 350)il o f purified 
cells in HEPES buffer were first equilibrated wi th 50| i l o f the tested agonist and 
50ul o f the tested antagonist for 10 minutes at 37°C. 50|ul o f lOx secretagogues 
were then added to the test tubes and incubated w i th the cells for further 10 
minutes before addition o f ice cold buffer. For histamine release experiments 
without incubation w i th agonists, 350|al o f purif ied cells and 50|ul o f the tested 
antagonist were equilibrated for 10 minutes at 37°C. After 10 minutes, 50}il o f the 
tested agonist and 50|_il o f lOx secretagogues were added together to test tubes and 
incubated for further 10 minutes before addition o f ice cold buffer. 
Results are expressed as mean 土 SEM and are corrected for the spontaneous'^ 
histamine release. Statistical analysis is performed using the—Student's t-test. Since 
the K i required for the various antagonists at their specific receptors are around 




4丄1, Effects of Al receptor antagonist DPCPX on modulations of anti-IgE 
induced histamine release by adenosine receptor agonists 
The A l adenosine receptor antagonist DPCPX had no effect on the spontaneous 
histamine release f rom rat peritoneal mast cells incubated in buffer alone. DPCPX 
also d id not show any enhancement on anti-IgE induced histamine release. Dose 
dependent potentiation o f anti-IgE induced histamine release by various adenosine 
receptor agonists (adenosine, N E C A , CCPA, CGS21680 and C l -MECA) were 
observed. The cells treated w i th A i adenosine receptor antagonist DPCPX did not 
show any change o f anti-IgE enhancing potency mediated by various adenosine 
receptor agonists as compared w i th the cells without A i antagonist treatment (Fig 
4.1,4.2, 4.3, 4.4 and 4.5). 
4.3.2. Effects of A2A receptor antagonist ZM241385 on modulations of anti-IgE 
induced histamine release by adenosine receptor agonists 
The A2A adenosine receptor antagonist ZM241385 had no effect on the 
spontaneous histamine release from rat peritoneal mast cells incubated in buffer 
alone. ZM241385 also did not show any enhancement on anti-IgE induced 
、 
histamine release. The cells treated w i th selective A2A adenosine receptor 
antagonist ZM241385 showed a general increase in the percentage potentiation 
induced by adenosine, N E C A and CGS21680 (Fig 4.6，4.7 and 4.9). Significant 
elevation o f adenosine induced potentiation was observed at 0.1 luM and l juM of 
adenosine w i th ZM241385 as compared wi th the potentiation induced by 
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adenosine alone. The max imum percentage potentiation for adenosine were 
103±8% and 78±5o/o at lOOj^M o f adenosine w i t h and without ZM241385 
respectively. The max imum percentage potentiation for adenosine were 74±8% 
and 57±8O/o at 10|LIM o f N E C A whereas 190±16O/O and 1 6 0 ± 1 5 O / O at lOOjLiM o f 
CGS21680 w i t h and without ZM241385 respectively. Un l ike adenosine, N E C A 
and CGS21680，anti-IgE enhancing o f CCPA and C l - M E C A were not reduced by 
the A2a adenosine receptor antagonist ZM241385 as compared w i th the cells 
wi thout antagonist treatment (Fig 4.8 and 4.10). The cells only showed a slight 
increase o f percentage potentiation - at the highest CCPA and C l -MECA 
concentration in the presence o f ZM241385. The max imum percentage 
potentiation were 95±9% and 65±9% at I O O ^ L M o f CCPA, whereas 1 1 5 ± 9 % and 
95±6% at l O p M o f C l - M E C A wi th and without ZM241385 respectively. 
4.3.3. Effects of A2B receptor antagonist MRS1706 on modulations of anti-IgE 
induced histamine release by adenosine receptor agonists 
The A2B adenosine receptor antagonist MR1706 had no effect on the spontaneous 
histamine release from rat peritoneal mast cells incubated in buffer alone. 
MRS 1706 also did not show any enhancement on anti-IgE induced histamine 
release. Similar to DPCPX, various agonists mediated potentiation o f anti-IgE 
induced histamine release was not affected by pretreated w i th the A2B receptor、 
antagonist-MRS1706 (Fig4.11, 4.12, 4.13, 4.14 and 4.15). The cells only showed 
a slight decrease o f percentage potentiation induced by adenosine in the presence 
o f MRS 1706. However, no significant reduction o f percentage potentiation 
mediated by adenosine was observed. 
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4丄4. Effects of As receptor antagonist VUF5574 on modulations of anti-IgE 
induced histamine release by adenosine receptor agonists 
The A3 adenosine receptor antagonist VUF5574 had no effect on the spontaneous 
histamine release from rat peritoneal mast cells incubated in buffer alone. 
VUP5574 also did not show any enhancement on anti-IgE induced histamine 
release. The cells treated wi th selective A3 adenosine receptor antagonist 
VUP5574 showed an apparent decrease o f percentage potentiation o f anti-IgE 
induced histamine release mediated by adenosine, CCPA, CGS21680 and 
C l -MECA as compared w i th cells without antagonist treatment (Fig 4.16, 4.18， 
4.19 and 4.20). On the other hand, cells treated w i th selective A3 adenosine 
receptor antagonist VUF5574 showed a general decrease o f N E C A induced 
potentiation. The maximum percentage potentiation were 50±5% and 60±8% at 
lO^iM o f NEC A wi th and without VUP5574 respectively (Fig 4.17). 
4.3,5, Further characterization of adenosine mediated modulation of anti-IgE 
histamine release using VUF5574 and ZM241385 
Since A3 "adenosine receptors and A2A adenosine receptors are suggested to exist 
on rat peritoneal mast cells, the effects o f adenosine were further characterized 
々 
with the A2a antagonist ZM241385 and the A3 antagonist VUF5574. 
Purified rat peritoneal mast cells were preincubated wi th different concentrations 
of adenosine receptor antagonist VUF5574 for 10 minutes before being challenged 
‘ wi th adenosine and anti-IgE in HEPES buffer. The spontaneous histamine release 
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o f rat peritoneal mast cells were 8±1% o f total cellular histamine and the anti-IgE 
induced histamine release were 13±2o/o.Tlie cells treated w i th the lO^iM of 
selective A3 adenosine receptor antagonist VUF5574 showed a general decrease in 
the percentage potentiation induced by adenosine and significant decrease o f 
percentage potentiation were observed at l |aM and lO f iM o f adenosine. The 
max imum percentage potentiation decreased from 73% to 45% at 100| iM of 
adenosine after being treated wi th l O ^ M VUF5574 (Fig 4.21). However, the cells 
treated w i th l | j ,M and 0.1 | i M o f the selective A3 adenosine receptor antagonist 
VUF5574 did not show any change o f anti-IgE enhancing potency as compared 
w i th the cells without antagonist treatment (Fig 4.22 and 4.23). Although the cells 
treated w i th 0.1 j i M o f selective A3 adenosine receptor antagonist VUF5574 
showed a slight increase in the percentage potentiation induced by adenosine, no 
significant change o f percentage potentiation was observed. 
- I n order to confirm the properties o f VUF5574 purely without interference by 
other adenosine receptors, the dose response o f VUF5574 was observed in the 
presence o f A2A adenosine receptor antagonist ZM241385. Purif ied rat peritoneal 
mast cells were preincubated wi th different concentrations o f the adenosine 
receptor antagonist VUF5574 and l |aM of ZM241385 for 10 minutes before being 
challenged wi th adenosine and anti-IgE in HEPES buffer. The spontaneous 
histamine release o f rat peritoneal mast cells were 10±1% o f total cellular'V 
histamine and the anti-IgE induced histamine release were 38±3o/o. The cells 
treated wi th lOj^M selective A3 adenosine receptor antagonist VUF5574 showed a 
general decrease in the percentage potentiation on anti-IgE induced histamine 
release mediated by adenosine. Significant decreases o f percentage potentiation 
94 
were also observed at l ^ i M and lO f iM o f adenosine wh ich was same as in the 
absence o f Z M 2 4 1 3 8 5 (Fig 4 . 2 4 ) . Moreover, cells treated w i th 1 | J . M o f the 
selective A3 adenosine receptor antagonist VUF5574 also did not show any change 
o f anti-IgE enhancing potency as compared w i th the cells in the absence o f A2A 
antagonist (Fig 4.25). 
Next the effects o f the A2A adenosine receptor antagonist ZM241385 were 
investigated when the A3 receptors were blocked w i th VUF5574. Purif ied rat 
peritoneal mast cells were preincubated w i th different concentrations ZM241385 
and 10|dM o f VUF5574 for 10 minutes before being challenged w i th adenosine 
and anti-IgE in HEPES buffer. The spontaneous histamine release o f rat peritoneal 
mast cells were 7±lo/o o f total cellular histamine and the anti-IgE induced 
histamine release were 31 土30/0。The cells treated w i t h I j ^ M and 0.1 jaM o f 
ZM241385 showed a general increase in the percentage potentiation on anti-IgE 
induced histamine release mediated by adenosine together w i th 10]LIM VUF5574. 
Significant increases o f percentage potentiation were observed at O.ljjJVI and l ) i M 
o f adenosine in the presence o f L | A M and 0.1|J,M Z M 2 4 1 3 8 5 (Fig 4 . 2 7 and 4 . 2 8 ) . 
The cells treated w i th 10|JM and O.OljaM of the ZM241385 did not show any 
change o f anti-IgE enhancing potency as compared w i th the cells in the absence o f 
A2A antagonist (Fig 4.26 and 4.29). 
- 咏 
4.3.6. Effects of theophylline on anti-IgE induced percentage potentiation in 
HEPES buffer 
Several literatures showed that low concentrations o f theophylline act by 
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antagonising A2A adenosine receptor, therefore different concentrations o f 
theophyll ine on anti-IgE induced percentage potentiation in HEPES buffer was 
studied. Puri f ied rat peritoneal mast cells and different concentrations o f 
theophyll ine were preincubated w i th 10 minutes before being challenged wi th 
adenosine and anti-IgE in HEPES buffer. The spontaneous histamine release o f rat 
peritoneal mast cells were 8±lo/o o f total cellular histamine and the anti-IgE 
induced histamine release were 36±2%. A l l concentrations o f theophyll ine had no 
any effects on the spontaneous histamine release from rat peritoneal mast cells 
incubated in buffer alone. Moreover, the cells treated w i t h different concentrations 
o f theophyll ine did not show any change o f anti-IgE enhancing (Fig 4.30，4.31， 
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Fig 4.1 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th l|u,M DPCPX for 10 
minutes before the addition o f adenosine and anti-IgE. Results are expressed as 
mean 士 SEM for n=5. Spontaneous histamine release was 12+1% o f the total 
cellular histamine and the anti-IgE induced histamine release was 28±2o/o. 
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Fig 4.2 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by NECA. Mast cells were preincubated w i th I jdM DPCPX and 1 
uni t /ml adenosine deaminase for 10 minutes before the addition o f NECA and 
anti-IgE. Results are expressed as mean 士 SEM for n=4. Spontaneous histamine 
release was 11±1% of the total cellular histamine and the anti-IgE induced 
histamine release was 31±2%. 
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Fig 4.3 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CCPA. Mast cells were preincubated w i th l |aM DPCPX and 1 unit/ml 
adenosine deaminase for 10 minutes before the addition o f CCPA and anti-IgE. 
Results are expressed as mean 士 SEM for n=5. Spontaneous histamine release was 
11 ±2% o f the total cellular histamine and the anti-IgE induced histamine release 
was 27±2o/o. 
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Fig 4.4 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CGS21680. Mast cells were preincubated w i th l ^ M DPCPX and 1 
uni t /ml adenosine deaminase for 10 minutes before the addition o f CGS21680 and 
anti-IgE. Results are expressed as mean 士 SEM for n=5. Spontaneous histamine 
release was 8±lo/o o f the totai cellular histamine and the anti-IgE induced 
histamine release was 20±5%. 
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Fig 4.5 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by Cl -MECA. Mast cells were preincubated wi th I j i M DPCPX and 1 
unit/ml adenosine deaminase for 10 minutes before the addition o f C l -MECA and 
anti-IgE. Results are expressed as mean 土 SEM for n二5. Spontaneous histamine 
‘ release was 8±lo/o o f the total cellular histamine and the anti-IgE induced 
histamine release was 28+2%. 
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Fig 4.6 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th IjLiM ZM241385 for 10 
minutes before the addition o f adenosine and anti-IgE. Results are expressed as 
mean 士 SEM for n=5. Spontaneous histamine release was 12±lo/o o f the total 
cellular histamine and the anti-IgE induced histamine release was 28土2o/o. * = p < 





] - » - N E C A only T 
I 7。- ^ ^ 
- 1 0 J r 
I 1 1 1 1 
0.01 0.1 1 10 100 
NECA 鋼 
Fig 4.7 Potentiation of anti-IgE (1/300) induced histamine release from RPMC 
mediated by NECA. Mast cells were preincubated with l|.iM ZM241385 and 1 
unit/ml adenosine deaminase for 10 minutes before the addition of NECA and 
anti-IgE. Results are expressed as mean 士 SEM for n=4. Spontaneous histamine 
release was 11 ±1% of the total cellular histamine and the anti-IgE induced 
histamine release was 31±2o/o. 
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Fig 4.8 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CCPA. Mast cells were preincubated w i th l ^ M ZM241385 and 1 
unit /ml adenosine deaminase for 10 minutes before the addition o f CCPA and 
anti-IgE. Results are expressed as mean 土 SEM for n=5. Spontaneous histamine 
release was ll±2o/o o f the total cellular histamine and the anti-IgE induced 
histamine release was 27±2%. 
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Fig 4.9 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CGS21680. Mast cells were preincubated wi th Ip iM ZM241385 and 
1 uni t /ml adenosine deaminase for 10 minutes before the addition o f CGS21680 
and anti-IgE. Results are expressed as mean 土 SEM for Spontaneous 
histamine release was 8±lo/o o f the total cellular histamine and the anti-IgE 




Cl-MECA I T 
[115-
i 9。-
1 ^ ^ 
2 4 0 - ^ ^ 
咨 15- ^ . 
- 1 0 -
I 1 1 1 1 
0.001 0.01 0.1 1 10 
Cl-MECA (^iM) 
Fig 4.10 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by C l -MECA. Mast cells were preincubated w i th l\iM ZM241385 and 1 
unit /ml adenosine deaminase for 10 minutes before the addition o f C l -MECA and 
anti-IgE. Results are expressed as mean 土 SEM for n=5. Spontaneous histamine 
release was 8±lo/o o f the total cellular histamine and the anti-IgE induced 
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Fig 4.11 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th l ^ M MRS 1706 for 10 
minutes before the addition o f adenosine and anti-IgE. Results are expressed as 
mean 土 SEM for n二5. Spontaneous histamine release was 12±lo/o o f the total 
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Fig 4.12 Potentiation o f anti-IgE (1/300) induced histamine release f rom RPMC 
mediated by NECA. Mast cells were preincubated w i th l | aM MRS 1706 and 1 
uni t /ml adenosine deaminase for 10 minutes before the addition o f N E C A and 
anti-IgE. Results are expressed as mean 土 SEM for n=4. Spontaneous histamine 
release was 11±1% o f the total cellular histamine and the anti-IgE induced 
histamine release was 31 土2o/o. 
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Fig 4.13 Potentiation of anti-IgE (1/300) induced histamine release from RPMC 
mediated by CCPA. Mast cells were preincubated with l\iM MRS 1706 and 1 
unit/ml adenosine deaminase for 10 minutes before the addition of CCPA and 
anti-IgE. Results are expressed as mean 士 SEM for n=5. Spontaneous histamine 
release was ll±2o/o of the total cellular histamine and the anti-IgE induced 
histamine release was 27±2o/o. 
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Fig 4.14 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CGS21680. Mast cells were preincubated w i th l\iM MRS 1706 and 1 
uni t /ml adenosine deaminase for 10 minutes before the addition o f CGS21680 and 
anti-IgE. Results are expressed as mean 土 SEM for n=5. Spontaneous histamine 
release was 8±lo/o o f the total cellular histamine and the anti-IgE induced 
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Fig 4.15 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by C l -MECA. Mast cells were preincubated w i th l)_iM MRS 1706 and 1 
uni t /ml adenosine deaminase for 10 minutes before the addition o f C l -MECA and 
anti-IgE. Results are expressed as mean 土 SEM for n=5. Spontaneous histamine 
release was 8±lo/o o f the total cellular histamine and the anti-IgE induced 
histamine release was 28±2o/o. 
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Fig 4.16 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th 1|LIM VUF5574 for 10 
minutes before the addition o f adenosine and anti-IgE. Results are expressed as 
mean 土 SEM for n=5. Spontaneous histamine release was 12±1% of the total 
cellular histamine and the anti-IgE induced histamine release was 28±2o/o. 
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Fig 4.17 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by NECA. Mast cells were preincubated w i th l ^ M VUF5574 and 1 
uni t /ml adenosine deaminase for 10 minutes before the addition o f N E C A and 
anti-IgE. Results are expressed as mean 土 SEM for n=4. Spontaneous histamine 
release was 11±1% o f the total cellular histamine and the anti-IgE induced 
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Fig 4.18 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CCPA. Mast cells were preincubated w i th l | i M VUF5574 and 1 
uni t /ml adenosine deaminase for 10 minutes before the addition o f CCPA and 
anti-IgE. Results are expressed as mean 土 SEM for n=5. Spontaneous histamine 
release was 11 土2% o f the total cellular histamine and the anti-IgE induced 
histamine release was 27±2%. 
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Fig 4.19 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by CGS21680. Mast cells were preincubated wi th l\iM VUF5574 and 1 
unit /ml adenosine deaminase for 10 minutes before the addition o f CGS21680 and 
anti-IgE. Results are expressed as mean 土 SEM for n=5. Spontaneous histamine 
release was 8±lo/o o f the total cellular histamine and the anti-IgE induced 
histamine release was 20±5%. 
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Fig 4.20 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by C l -MECA. Mast cells were preincubated w i th l|_iM VUF5574 and 1 
uni t /ml adenosine deaminase for 10 minutes before the addition o f C l -MECA and 
anti-IgE. Results are expressed as mean 士 SEM for n=5. Spontaneous histamine 
release was 8±lo/o o f the total cellular histamine and the anti-IgE induced 
histamine release was 28士2o/o. 
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Fig 4.21 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th 10|uM VUF5574 for 10 
minutes before the addition o f adenosine and anti-IgE. Results are expressed as 
mean 土 SEM for n=6. Spontaneous histamine release was 8±1% of the total 
cellular histamine and the anti-IgE induced histamine release was 13±2%. * = p < 
0.05, * * 二 p < 0.01, wi th VUP5574 vs without VUF5574 preincubations values. 
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Fig 4.22 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th l |aM VUF5574 for 10 
minutes before the addition of adenosine and anti-IgE. Results are expressed as 
mean 土 SEM for n=6. Spontaneous histamine release was 8±lo/o o f the total 
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Fig 4.23 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th 0.1 j^M VUP5574 for 
10 minutes before the addition of adenosine and anti-IgE. Results are expressed as 
mean 土 3 E M for n=6. Spontaneous histamine release was 8±lo/o o f the total 
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Fig 4.24 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th lO j iM VUF5574 or 
without lOi^M VUF5574 together wi th l ^ M ZM241385 for 10 minutes before the 
addition o f adenosine and anti-IgE. Results are expressed as mean 土 SEM for n=7. 
Spontaneous histamine release was 10+1% o f the total cellular histamine and the 
anti-IgE induced histamine release was 38+3%. * * = p < 0.01, * * * 二 p < 0.001 
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Fig 4.25 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th I j xM VUF5574 or 
without l ^ M VI IF5574 together w i th I j i M ZM241385 for 10 minutes before the 
addition o f adenosine and anti-IgE. Results are expressed as mean 士 SEM for n=7. 
Spontaneous histamine release was 10±1% of the total cellular histamine and the 
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Fig 4.26 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th lO j iM ZM241385 or 
without 10| iM ZM241385 together w i th lO j iM VUF5574 for 10 minutes before 
the addition o f adenosine and anti-IgE。Results are expressed as mean 土 SEM for 
n=8. Spontaneous histamine release was 7±lo/o o f the total cellular histamine and 
the anti-IgE induced histamine release was 31 ±3%. * * 二 p < 0.01, * * * = p < 0.001 
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Fig 4.27 Potentiation o f anti-IgE (1/300) induced histamine release f rom RPMC 
mediated by adenosine. Mast cells were preincubated w i t h l | j .M ZM241385 or 
wi thout l ) i M ZM241385 together w i th lO]iM VUF5574 for 10 minutes before the 
addit ion o f adenosine and anti-IgE. Results are expressed as mean 土 SEM for n=8. 
Spontaneous histamine release was 7±lo/o o f the total cellular histamine and the 
anti-IgE induced histamine release was 31±3%. * = p < 0.05, * * = p < 0.01, w i th 
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Fig 4.28 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th 0.1|LIM ZM241385 or 
wi thout 0 .1 ^ iM Z M 2 4 1 3 8 5 together w i th 10|LIM V U F 5 5 7 4 for 10 minutes before 
the addit ion o f adenosine and anti-IgE. Results are expressed as mean 土 SEM for 
n二8. Spontaneous histamine release was 7±lo/o o f the total cellular histamine and 
the anti-IgE induced histamine release was 31±3o/o. * = p < 0.05，with ZM241385 
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Fig 4.29 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th lOnM ZM241385 or 
wi thout LONM Z M 2 4 1 3 8 5 together w i th 10|LIM V U F 5 5 7 4 for 10 minutes before 
the addition o f adenosine and anti-IgE. Results are expressed as mean 土 SEM for 
n=8. Spontaneous histamine release was 7±lo/o o f the total cellular histamine and 
the anti-IgE induced histamine release was 31+3%. 
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Fig 4.30 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th 10|J-M theophylline for 
10 minutes before the addition o f adenosine and anti-IgE. Results are expressed as 
mean 士 SEM for n=4. Spontaneous histamine release was 8±lo/o o f the total 
cellular histamine and the anti-IgE induced histamine release was 36±2%. 
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Fig 4.31 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th l \ i M theophylline for 
10 minutes before the addition o f adenosine and anti-IgE. Results are expressed as 
mean 士 SEM for n=4. Spontaneous histamine release was 8士 1 o/o o f the total 
cellular histamine and the anti-IgE induced histamine release was 36±2%. 
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Fig 4.32 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated w i th O.ljjJVI theophylline for 
10 minutes before the addition o f adenosine and anti-IgE. Results are expressed as 
mean 土 SEM for n=4. Spontaneous histamine release was 8±lo/o o f the total 
cellular histamine and the anti-IgE induced histamine release was 36+2%. 
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Fig 4.33 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by adenosine. Mast cells were preincubated wi th lOnM theophylline for 
10 minutes before the addition of adenosine and anti-IgE. Results are expressed as 
mean 士 SEM for n二4. Spontaneous histamine release was 8±lo/o o f the total 




In order to further investigate i f the effects o f adenosine were mediated through 
the adenosine receptors as suggested in the agonist studies, effects o f specific 
antagonist o f the adenosine receptor subtypes were studied. None o f the adenosine 
receptor antagonist showed any effects on spontaneous histamine release and 
anti-IgE induced histamine release. First o f all, the A i antagonist DPCPX was 
tested w i th different receptor agonists. None o f the cells showed any change of 
anti-IgE enhancing histamine release induced by various agonists in the presence 
o f A l antagonist DPCPX. It means that A i adenosine receptor subtype should not 
exist in the rat peritoneal mast cells. Secondly, the A2A antagonist ZM241385 was 
tested w i th different adenosine receptor agonists. AIA antagonist ZM241385 in 
general had an enhancement effects on the percentage potentiation induced by 
various agonists, in particular significant increase o f potentiation mediated by 
adenosine was observed. This confirmed the agonist studies that activation of A2A 
receptor induced inhibit ion o f anti-IgE induced histamine release, hence when the 
A2A adenosine receptor in rat peritoneal mast cells are blocked by the A2A receptor 
antagonist, the potentiation effect is enhanced. Fol lowing A2A antagonist, the A2B 
antagonist MRS 1706 was tested wi th different receptor agonists. A2B antagonist 
MRS 1706 in general had no effects on percentage potentiation induced by various 
agonists. Although, the A2B antagonist MRS 1706 had marginal demonstrated 
inhibitory effect on the effect o f adenosine and an earlier study suggested that 
adenosine-induced enhancement o f mediator release may mediate through the A2B 
receptor subtype in rat (Feoktistov et aL, 1995), the inhibitory effect was only 
observed on the effect of adenosine and the inhibitory effect on adenosine was also 
not significant. Furthermore, no inhibitory effects were observed on the effect of 
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other agonists. Hence, it is believed that A2B adenosine receptor does not exist in 
rat peritoneal mast cells. More and more recent reports suggested that the A3 
receptor promoted the mast degranulation rather than other adenosine receptor 
subtypes. Ti l ley (2000) proved that the abil i ty o f adenosine to enhance 
antigen-induced degranulation through activation o f A3 adenosine receptor in 
murine bone marrow-derived mast cells (Ti l ley et al,, 2000). Besides, it was 
showed that the A3 adenosine receptor played an important role in 
adenosine-mediated murine lung mast cell degranulation (Zhong et al., 2003). In 
the current study, A3 receptor antagonist VUF5574 showed a slight reduction o f 
the potentiation effect o f adenosine, NECA, CCPA, CGS21680 and C l -MECA 
induced potentiation as compared wi th the cells without A3 antagonist treatment. It 
is obvious that i f A3 receptor existed on rat peritoneal mast cells, A3 receptor 
antagonist should have significant inhibitory effect on anti-IgE induced histamine 
release. However, the current study only showed that A3 receptor antagonist had a 
tendency o f inhibitory effect on rat peritoneal mast cells. It seems that the 
concentration o f l | i M VUF5574 was not high enough to show a significant result. 
Besides, our results also showed that other adenosine receptor antagonists could 
not significantly inhibit the corresponding receptor potentiation effect. It may due 
to the concentration o f antagonist was not high enough to show a significant result. 
I f the concentration was higher, significant result may be observed. The reason 
why the concentration l \ i M was chosen as the tested concentration is because the 
、 
aff inity o f various antagonists at their specific receptor is around I nM , the use of 
l | i M ought to be sufficient according to the reported K i value (Table 4.1). A 
literature which studied the effect o f adenosine in similar mast cell system also 
showed that IjjJVI o f adenosine receptor antagonist was sufficient to block the 
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corresponding adenosine receptor subtype in Wistar rat peritoneal mast cell 
(Dexter et al., 1999). Unfortunately, our current study showed that l[iM adenosine 
receptor antagonist was sti l l not high enough to show the significant result. 
Hence, different concentrations o f the A3 antagonist VUF5574 on anti-IgE 
enhancing histamine release induced by adenosine was investigated. The results 
showed that lO^iM o f A3 antagonist VUF5574 had a significant inhibitory effect 
on percentage potentiation mediated by adenosine. Significant inhibitions were 
also observed at 1 and lOf iM of adenosine. However, 1 and O.ljjJVI A3 antagonist 
had no significant inhibitory effect on percentage potentiation as compare wi th the 
cell without adding the antagonist. Nevertheless, the significant inhibit ion of 
percentage potentiation mediated by adenosine in the presence o f lO f iM of A3 
antagonist VUF5574 could further confirm the existence o f A3 receptor on rat 
peritoneal mast cell. 
Potentiation by A3 agonist may be suppressed by the concomitant activation of A2A 
receptors, the significance of suppression mediated by A3 antagonist may be 
reduced. Hence, the inhibitory potency o f A3 antagonist VUF5574 was 
reinvestigated after blocking the A2A receptors w i th the A2A antagonist ZM241385. 
The existence o f A2A and A3 receptors on mast cells was suggested by our study so — 
far, it would be interesting to investigate i f adding A2 antagonist to block the A2A-. 
-V 
receptor would produce results which better reflect the activity purely coming 
from the A3 antagonist and vice verse. These results could directly show the effect 
o f adenosine on one subtype o f adenosine receptor and the estimation of 
antagonist activity can be performed without influence by the other adenosine 
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receptor subtype. First o f all, the effect o f l ^ i M A2A antagonist ZM241385 together 
w i t h different concentrations o f the A3 antagonist VUF5574 was investigated on 
adenosine potentiation o f anti-IgE induced histamine release. Similar to 
experiments wi thout addition o f ZM241385, VUF5574 demonstrated a significant 
inhib i tory effect on adenosine mediated percentage potentiation only at lOj^M. No 
significant reduction o f adenosine induced potentiating effect was st i l l observed 
w i t h l | i M VUF5574. In the presence o f l ^ i M ZM241385, the inhibi tory effect o f 
VUF5574 on adenosine mediated potentiation became more significant at lower 
concentrations o f adenosine. It suggested that the activation o f A2A adenosine 
receptor reduced the potentiation potency o f adenosine. 
The effect o f 10|JM together w i th different concentrations o f the A2A antagonist 
ZM241385 was also investigated on adenosine potentiation o f anti-IgE induced 
histamine release. ZM241385 showed a dose-dependent enhancing effect on 
adenosine mediated potentiation at l | i M and 0.1|LLM. The addition o f Z M 2 4 1 3 8 5 
blocked A2A adenosine receptor and thus adenosine became more potent to bind A3 
adenosine receptor. Therefore, the potentiation mediated by adenosine was 
enhanced in the presence o f ZM241385.Similar to experiments without addition o f 
VUP5574, ZM241385 demonstrated a significant enhancement effect on 
.adenos ine mediated percentage potentiation at I j^M. No significant enhancement 
o f adenosine induced potentiating effect were observed w i th lO f iM and 0.01jLiM:v 
ZM241385. However, l O ^ M o f ZM241385 did not fo l low the dose-dependent 
enhancing action. A literature investigating the activities o f AIA antagonist pointed 
out that ZM241385 had some problems about the specificity and solubility. The 
study showed ZM241385 bind also wi th an aff inity to other adenosine receptor 
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subtypes such as A2B or A3 receptor (Cacciari et al., 2003). Therefore, it is possible 
that ZM241385 may not selectively bind to A2A adenosine receptor at lOpM. 
When focused on K i value o f ZM241385 (Table 4.1), i t also showed that 
ZM241385 had a binding aff inity to A i or A3 adenosine receptor at high 
concentrations, hence ZM241385 may non-selectively bind to other adenosine 
receptor subtypes at 10|aM. These experiments further consolidated our suggestion 
that the biphasic effect induced by adenosine which the inhibitory effect induced 
by adenosine was due to the activation o f A2A adenosine receptor at low 
concentrations whereas the potentiating effect was due to the activation o f A3 
adenosine receptor at high concentrations. Hence, our study confirmed that the 
existence o f A2A and A3 adenosine receptor on the rat peritoneal mast cells. In 
additional to the pharmacological agents, determination o f gene or protein 
expression can be further performed in order to confirm the existence o f adenosine 
receptors. 
The result showed on Fig 4.16 and Fig 4.22 was testing the histamine release wi th 
same concentration o f A3 antagonist treatment. However, the results came from 
different batches o f rats. Especially, the result o f Fig 4.22 was performed from a 
batch o f rats diets were changed。Moreover, the result o f Fig 4.16 and Fig 4.22 
were relatively consistent and hence suggested that the changing o f diet did not 
alter the effect o f adenosine induced potentiation. 
It has been pointed out that in human mast cells, theophylline might inhibit 
anti-IgE induced histamine release through competitive antagonism o f adenosine 
(Delmich et al., 1985). Yasui (2000) suggested that theophylline had an 
immunomodulatory action on neutrophil apoptosis via a mechanism of A2A 
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antagonism (Yasui et al., 2000). Besides, a cl inical report suggested that 
theophyll ine may improve Parkinson's disease through A2A adenosine receptor 
antagonism (Agematsu et al., 2000). However, contradictory reports suggested 
that theophylline binds to the A2B receptor rather than AIA receptor in human lung 
mast cells (Feoktistov et aL, 1998). Besides, it showed that theophylline may 
contribute to anti-asthmatic effect via A2B receptor antagonism (Barbanoj et al., 
2002). From the biochemical point o f view, it was suggested that theophylline 
inhibited the A2B adenosine receptor gene expressions. Theophylline might 
antagonize adenosine by inhibit ing A2B adenosine receptor m R N A (Yang et al., 
2001). It was hence interesting to investigate whether theophylline might inhibit 
the adenosine-mediated potentiation o f anti-IgE histamine release on rat peritoneal 
mast cells. Different concentrations o f theophylline were performed to study the 
effects o f theophylline. While, the results observed that none o f the concentrations 
showed an enhancement or inhibitory effect on adeno sine-mediated histamine 
release. Our previous studies suggested the existence o f A2A receptor on the 
peritoneal mast cells, therefore, theophylline does not work as an A2A antagonist 
on the rat peritoneal mast cells. 
4.5. Conclusion 
Different literatures identified that the activation o f mast cell might be mediated 
through A2B or A3 adenosine receptor (Feoktistov et aL, 1998; Ti l ley et al., 2000). 
Our current study did not observe any direct stimulatory affect o f adenosine on rat 
peritoneal mast cells but revealed that adenosine can mediate anti-IgE induced 
histamine release through the A2A and A3 adenosine receptor subtypes. A2A 
antagonist had an enhancement effect on adeno sine-mediated percentage 
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potentiation, whi le, A3 antagonist had an inhibitory effect on adenosine-mediated 
percentage potentiation. Our agonist study showed that A2A agonist mediated 
inhibi tory effect, whi le other agonists had only potentiating effect on 
adenosine-mediated anti-IgE histamine release. B y summarizing the results wi th 
agonists and antagonists, it was confirmed that the biphasic effect induced by 
adenosine was a combination action o f A2A and A3 receptor. Adenosine mediated 
inhibi tory effect was through the activation o f A2A receptor at low concentrations, 
whereas adenosine mediated potentiating effect was through the activation o f A3 
receptor at high concentrations on SD rat peritoneal mast cells. Hence, A2A and A3 
adenosine receptor subtypes were existed on SD rat peritoneal mast cell. 
In addition, theophylline was suggested to be A2A or A2B antagonist on the mast 
cell (Barbanoj et al., 2002; Yasui et al, 2000). In our previous studies confirmed 
that the existence o f A2A and A3 receptor subtypes on the rat peritoneal mast cell, 
whereas, the results observed that none o f the concentration o f theophylline 
showed an enhancement or inhibitive effect on adenosine-mediated histamine 
release. Hence, theophylline did not show as an A2A antagonist on the rat 




DPCPX ZM241385 MRS 1706 VUF5574 
Al 0.9 257 37.6 >10000 
A2a 450 1.8 548 >10000 
A2b N/A 16.5 1.4 N/A 
A3 5300 270 N/A 4 
Table 4.1 K i (nM) o f different adenosine receptor antagonist in mast cells 
N / A = not available 
Datas summerized from Keddie et. al, (1996), Kiec-Kononowicz et. al, 









The activation o f mast cells could be achieved through two ways: immunological 
activation and non-immunological activation. Immunological activation involved 
IgE, high aff ini ty IgE receptor and specific antibodies, whereas, 
non-immunological activation involved chemical, temperature or physical 
stimulus (Foreman et al., 1981; Ishizaka, 1981). Immunological activation o f the 
mast cell is provided by cross-linking o f IgE antibody molecules and then bridging 
o f antibody receptor sites on the plasma membrane (Ishizaka, 1981). On the other 
hand, compound 48/80 and calcium ionophore A23187 are chemicals for 
non-immunological activation. Non-immunological activation usually bypass 
some o f the init ial steps of antigen induce release. For example, 
non-immunological activation usually bypasses the cross-linking o f IgE antibody 
molecule and directly activates the G-protein. 
Early study showed that adenosine potentiated mediator release induced by 
various secretagogues in rat mast cells. The various secretagogues were anti-IgE, 
compound 48/80 and calcium ionophore A23187 (Marquardt et al., 1978). Similar 
study also reported that compound 48/80, anti-IgE and calcium ionophore A23187 
induced histamine release from rat mast cells (Gruber et al., 1986). Interestingly, 一 
two other reports suggested that anti-IgE and calcium ionophore induced the 
"B-
histamine release but not for compound 48/80 in human mast cells (Bridges et al,, 
1991; Kopicky-Burd et al., 1988). Hence, this study aims to clarify the effects of 
adenosine on histamine release induced by various secretagogues in rat peritoneal 
mast cells. 
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There was a long history about the role o f calcium in mast cells. In the 1950s, the 
pioneer scientists Mongar and Schlid started to show that optimal anaphylactic 
secretion o f histamine f rom mast cells in the fragments o f guinea-pig lung required 
the presence o f extracellular calcium ions (Monger et al., 1958). This observation 
attracted the attention on the role o f calcium on secretion o f histamine release on 
the mast cell activation, therefore, a variety o f experiments were performed on 
different animals or different sources o f isolated mast cells in order to investigate 
the role o f calcium. In view o f the dependence o f histamine release on calcium 
ions, at late 1970s, Foreman, Hallett and Mongar investigated the cation fluxes 
fo l lowing cellular activation. They showed that stimulation o f mastocytes by the 
antigen-antibody reaction or by other secretagogues caused an uptake of 
radiolabelled calcium from the external medium (Foreman et al., 1977). Moreover, 
there are also confl icting reports from different laboratories. Particularly one year 
after the Foreman studies, Grosman and Diamant found that there was no 
correlation between histamine release and calcium uptake (Grosman et al., 1978). 
Similar reservations have been expressed by Sugiyama (Sugiyama, 1971). Another 
scientist Kaimo (1973) used the simple micro-injection o f the cation into rat 
mesenteric mast cells to study the role o f calcium in histamine release secretion 
(Kaimo et al., 1973). The micro-injection produced a rapid and characteristic 
degranulation o f the cells essentially identical to that observed fol lowing 
immunological activation or selective pharmacological stimulation. The effect 
could not be reproduced by injection o f magnesium or potassium ions except 
calcium. These results strongly indicated that a rise in the intracellular 
concentration of calcium ions was itself a sufficient condition for the induction of 
exocytosis. The reasons for these differing results were not clear but base on the 
conflicting results, it indicated that further investigations were required to assess 
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the value o f calcium in histamine secretion. Hence, it is interested to investigate 
whether adenosine mediated enhancement o f anti-IgE induced histamine release is 
trigger directly by the mobil ization o f intracellular calcium stores or promotes 
inf lux o f the cation from the extracellular environment. 
In current study, we attempted to investigate the important o f extracellular calcium 
on anti-IgE induced histamine release. Then, the effect o f adenosine on compound 
48/80 and calcium ionophore A23187 induced histamine release were also studied. 
Furthermore, it is interested to study the source o f calcium in adenosine mediated 
enhancement o f anti-IgE induced histamine release on rat peritoneal mast cells. 
Finally, endogenous adenosine inside the mast cells would change into inosine 
after using the adenosine deaminase, therefore, the effects o f inosine and the 
effects o f adenosine receptor antagonists on inosine mediated enhancement of 
anti-IgE induced histamine release were studied. 
5.2. Materials and methods 
The materials and methods used are described in chapter 2. The HEPES and 
calcium free buffers were prepared using nanopure water provided by 
pharmacology department. The purified rat peritoneal mast cells were resuspended 
in HEPES or calcium free buffer. For histamine release experiments without 
antagonist, 400|al o f purif ied cells were first equilibrated in HEPES or calcium 
free buffer for 10 minutes at 37°C. Subsequently, 50jal o f lOx secretagogues and 
50|i l o f the tested drug were added to the test tubes and incubated for further 10 
minutes before addition of ice cold buffer. For the histamine release experiments 
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wi th adenosine deaminase, 400^x1 o f purif ied cells and 50| i l o f one unit per m l 
adenosine deaminase were equilibrated in HEPES buffer for 10 minutes at 37。C. 
After 10 minutes incubation, 50^1 o f lOx secretagogues were added to the test 
tubes and incubated for further 10 minutes before addition o f ice cold buffer. For 
the histamine release experiments wi th adenosine receptor antagonist, 350)^1 o f 
puri f ied cells and 50}il o f the tested antagonist were equilibrated for 10 minutes at 
37。C. Subsequently, 50[i l o f the tested agonist and 50)J1 o f lOx secretagogues were 
added together to test tubes and incubated for further 10 minutes before addition 
o f ice cold buffer. 
5.3. Results 
53,1, Effects of anti-IgE induced histamine release in calcium free and HEPES 
buffers 
In order to investigate the source o f calcium during adenosine mediated mast cell 
activation, purif ied rat peritoneal mast cells were equilibrated in the two buffers, 
i.e. HEPES and calcium free buffers at 37。C for 10 minutes before being 
challenged wi th anti-IgE. Results demonstrated that anti-IgE dose dependently 
induced histamine release in HEPES buffer. The maximum level o f anti-IgE 
induced histamine release was 25+2% at 1/100 of anti-IgE. Whereas, the anti-IgE 
induced histamine release was abolished in calcium free buffer over the anti-IgE 
concentration range tested. The maximum anti-IgE induced histamine release was 
only about 5% in calcium free buffers. It is obvious that the histamine releasing 
effect o f anti-IgE was significantly reduced in the calcium free buffers (Fig 5.1) 
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5,3.2, Effects of adenosine on anti-IgE induced histamine release in calcium 
free buffer 
In order to characterize the important o f calcium on adenosine mediated mast 
activation, effects o f adenosine on anti-IgE induced histamine release in the 
presence o f adenosine antagonists in calcium free buffer were studied. Adenosine 
mediated enhancement o f anti-IgE induced histamine release was abolished in 
calcium free buffer over the adenosine concentration range tested. The maximum 
levels o f anti-IgE induced histamine release was <20% for both sets o f experiment 
(Fig 5.2). 
5.5.5. Effects of adenosine deaminase on compound 48/80 induced histamine 
release from rat peritoneal mast cells 
Purif ied rat peritoneal mast cells and a dose concentration o f adenosine deaminase 
were equilibrated in the HEPES buffers at 37。C for 10 minutes before being 
challenged w i th l|Lig/ml compound 48/80. Relatively constant level o f compound 
48/80 induced histamine release o f 35±3% was observed f rom the concentration 
-range 0.01 unit /ml to 0.1 unit/ml o f adenosine deaminase. There was an instant 
decrease o f compound 48/80 induced histamine release f rom 34% to 23% at the 
concentrations 0.1 unit /ml to 1 unit/ml o f adenosine deaminase. Then, relatively：、^ 
constant level o f compound 48/80 induced histamine release about 18±4% was — 
observed from the concentration range 1 unit/ml to 10 unit/ml o f adenosine 
deaminase (Fig 5.3). 
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53.4. Effects of adenosine on compound 48/80 induced histamine release in 
HEPES buffer 
Puri f ied rat peritoneal mast cells were equilibrated in the HEPES buffers at 37°C 
for 10 minutes before being challenged w i th adenosine and compound 48/80. The 
spontaneous histamine release o f rat peritoneal mast cells was 6±lo/o o f total 
cellular histamine and the compound 48/80 induced histamine release was 53±4%. 
Adenosine mediated a general increase o f potentiation on compound 48/80 
induced histamine release from about 44% to 55%. However, there was no 
significant potentiation on compound 48/80 induced histamine release at the 
concentration range tested (Fig 5.4). 
5.5.5. Effects of adenosine deaminase on A23187 induced histamine release 
from rat peritoneal mast cells 
Purif ied rat peritoneal mast cells and a dose concentration o f adenosine deaminase 
were equilibrated in the HEPES buffers at 37°C for 10 minutes before being 
challenged w i th 0。1|JM calcium ionophore A23187. The spontaneous histamine 
release o f rat peritoneal mast cells was 8土lo/。of total cellular histamine and the 
calcium ionophore A23187 induced histamine release was 53±3%. A 
-
dose-dependent decrease o f calcium ionophore A23187 induced histamine release'' 
was observed f rom the concentration 0.01 uni t /ml to 10 unit /ml o f adenosine 
deaminase. The calcium ionophore A23187 induced histamine release was 
decreased from the maximum 47% to the min imum 26% (Fig 5.5). 
144 
5.3.6, Effects of adenosine on calcium ionophore A23187 induced histamine 
release in HEPES buffer 
Purif ied rat peritoneal mast cells were equilibrated in the HEPES buffers at 37°C 
for 10 minutes before being challenged w i th adenosine and calcium ionophore 
A23187. The spontaneous histamine release o f rat peritoneal mast cells was 6±lo/o 
o f total cellular histamine and the calcium ionophore A23187 induced histamine 
release was 74+3%. Adenosine also mediated a general increase o f potentiation on 
calcium ionophore A23187 induced histamine release f rom 65% to 80%. However, 
there was also no significantly potentiation on calcium ionophore A23187 induced 
histamine release at the concentration range used (Fig 5.6). 
5.3.7. Effects of adenosine receptor antagonists on inosine mediated 
enhancement of anti-IgE induced histamine release 
Purif ied rat peritoneal mast cells, 1 | i M of adenosine receptor antagonist and one 
unit o f adenosine deaminase were preincubated w i th 10 minutes before being 
challenged wi th inosine and anti-IgE in HEPES buffer. The spontaneous histamine 
release o f rat peritoneal mast cells was 11 ±2% o f total cellular histamine and the 
anti-IgE induced histamine release was 45±4o/o. Dose dependent potentiation on 
inosine mediated enhancement of anti-IgE induced histamine release was observed。 
from 5% to 52% in the concentration range used. The cells treated with the 
selective A i adenosine receptor antagonist DPCPX, A2A adenosine receptor 
antagonist ZM241385, A2B receptor antagonist MRS 1706 and A3 adenosine 
receptor antagonist VUF5574 nearly did not show any change of anti-IgE 
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enhancing potency as compared w i th the cells without antagonist treatment (Fig 
5.7, 5.8, 5.9 and 5.10). 
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Fig 5.1 Ant i - IgE (1/300) induced histamine release f rom RPMC in calcium free 
and HEPES buffers. Mast cells were equilibrated for 10 minutes at 37。C in 
relevant buffers before the addition o f anti-IgE. Spontaneous histamine release 
was <20% o f the total cellular histamine for all two treatments. Results are 
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Fig 5.2 Effects o f adenosine on anti-IgE (1/300) induced histamine release from 
RPMC in calcium free buffer. Mast cells were reacted wi th adenosine and anti-IgE 
simultaneously for 10 minutes. Results are expressed as mean 土 SEM for n=4. 
Spontaneous histamine release was 11±1% o f the total cellular histamine and the 
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Fig 5.3 Effects o f adenosine deaminase ( A D A ) on compound 48/80 (1 j ig/ml) 
induced histamine release from RPMC. Mast cells were preincubated for 10 
minutes before the addition o f compound 48/80. Results are expressed as mean 土 
SEM for n=8. Spontaneous histamine release was 8±lo/o o f the total cellular 
histamine and the compound 48/80 induced histamine release was 26±3%. 
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Fig 5.4 Effects o f adenosine on compound 48/80 ( l | i g /m l ) induced histamine 
release f rom RPMC. Mast cells were preincubated for 10 minutes before the 
addition o f adenosine and compound 48/80. Results are expressed as mean 土 SEM 
for n=4. Spontaneous histamine release was 6±lo/o o f the total cellular histamine 
and the compound 48/80 induced histamine release was 53+4%. 
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Fig 5.5 Effects o f adenosine deaminase ( A D A ) on A23187 (0.1 | iM) induced 
histamine release from RPMC. Mast cells were preincubated for 10 minutes before 
the addition o f A23187. Results are expressed as mean 士 SEM for n=6. 
Spontaneous histamine release was 8±lo/o o f the total cellular histamine and the 
A23187 induced histamine release was 53+3%. 
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Fig 5.6 Effects o f adenosine on ionophore A23187 (O.ljaM) induced histamine 
release f rom RPMC. Mast cells were preincubated for 10 minutes before the 
addit ion o f adenosine and ionophore A23187. Results are expressed as mean 土 
S E M for n=4. Spontaneous histamine release was 6士P/o o f the total cellular 
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Fig 5.7 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by Inosine. Mast cells were preincubated w i th l\iM DPCPX and 1 
unit /ml adenosine deaminase for 10 minutes before the addition o f inosine and 
anti-IgE. Results are expressed as mean 土 SEM for n二4. Spontaneous histamine 
release was ll±2o/o o f the total cellular histamine and the anti-IgE induced 
histamine release was 45±4%. 
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Fig 5.8 Potentiation o f anti-IgE (1/300) induced histamine release f rom RPMC 
mediated by Inosine. Mast cells were preincubated w i th 1|LIM Z M 2 4 1 3 8 5 and 1 
uni t /ml adenosine deaminase for 10 minutes before the addition o f inosine and 
anti-IgE. Results are expressed as mean 土 SEM for n=4. Spontaneous histamine 
release was ll±2o/o o f the total cellular histamine and the anti-IgE induced 
histamine release was 45±4%. 
、 
154 
6 0 i 
一 lno+MRS1706 •“ 
§ 50誦 —»— Inosine 卜 
I： ^ ^ ^ 
S. 20- ^ ^ ^ 
0-1 
I 1 1 1 i 
0.1 1 10 100 1000 
Inosine (|aM) 
Fig 5.9 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by Inosine. Mast cells were preincubated w i th l \ i M MRS 1706 and 1 
unit /ml adenosine deaminase for 10 minutes before the addition o f inosine and 
anti-IgE. Results are expressed as mean 土 SEM for n=4. Spontaneous histamine 
release was ll±2o/o o f the total cellular histamine and the anti-IgE induced 
histamine release was 45±40/0. 
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Fig 5.10 Potentiation o f anti-IgE (1/300) induced histamine release from RPMC 
mediated by Inosine. Mast cells were preincubated w i th l |aM VUF5574 and 1 
uni t /ml adenosine deaminase for 10 minutes before the addition o f inosine and 
anti-IgE. Results are expressed as mean 土 SEM for n=4. Spontaneous histamine 
release was 11 ±2% o f the total cellular histamine and the anti-IgE induced 




Our previous results showed that adenosine mediated potentiation effect on anti 
IgE-induced histamine release. It is interested to study the important o f calcium 
ion on the immunological anti-IgE activation and adenosine enhanced anti-IgE 
induced histamine release. The histamine release induced by anti-IgE was 
measured in calcium free or HEPES buffer. It was observed that there was a 
dose-dependent increase o f anti-IgE induced histamine release in HEPES buffer, 
while, the anti-IgE induced response was abolished in calcium free buffer over the 
anti-IgE concentration range tested. The adenosine enhanced anti-IgE induced 
histamine release was almost abolished in the experiment. Lots o f previous 
literatures had proofed that calcium played an important role in histamine release 
and mast cell degranulation (Foreman et aL, 1977; Foreman et al., 1981; Kanno et 
al., 1973). However, the source o f calcium could come from the extracellular 
inf lux or by the mobil ization of intracellular calcium stores (Rasmussen et al., 
1975). The current study showed that the effect o f adenosine was abolished in 
calcium free buffer condition, hence adenosine may enhance the calcium influx 
associated wi th anti-IgE induced mast cell activation. 
In order to further investigate i f facilitation o f extracellular calcium influx is a 
major mechanism for adenosine induced potentiation, the effect o f adenosine on 
mast cell histamine release induced wi th different secretagogues were investigated?^ 
Compound 48/80 and calcium ionophore A23187 were the secretagogues for 
non-immunological activation. The activation o f mast cells induced by compound 
48/80 bypasses any IgE receptor binding and is through direct activation of the 
heterotrimeric G protein. The activation o f G-protein leads to the tyrosine 
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phosphorylation o f phospholipase C (PLC) and activated PLC catalyses the 
hydrolysis o f phosphatidylinositol 4,5-bisphosphate (PIP2) into 
inositol-trisphosphate (IPs) and diacylglycerol (DAG). EP3 liberates Ca^^ from 
intracellular stores by activating specific receptors in the endoplasmic reticulum. 
I 
The increase o f intracellular Ca level leads to performed histamine release and 
mast cell degranulation. Therefore, the source o f calcium on compound 48/80 
induced histamine release is by the mobil ization o f intracellular calcium stores 
(Pearce, 1982). The current study showed that there was a slight decrease o f 
histamine release induced by compound 48/80 f rom 0.1 unit /ml to lun i t /ml o f 
adenosine deaminase. However, relatively constant level o f histamine release 
induced by compound 48/80 was observed in the concentration range o f adenosine 
tested. Hence, our study further confirmed that adenosine induced potentiation on 
mast cell histamine release through facilitation o f extracellular calcium influx. 
Calcium ionophore A23187 is another chemical for non-immunological activation 
o f mast cells. Calcium ionophore A23187 facilitates the transfer o f cations across 
l ip id bilayers or biological membranes. In the absence o f any stimulus, the cell 
membranes are intrinsically impermeable to biological ly important ions. The 
ionophores are organic molecules which translocate calcium ions directly from the 
exterior o f the cell into the interior by increasing the membrane permeability of 
calcium ions and hence bypassing the IgE receptor and the calcium channel 
(Pearce, 1982; Peachell et al., 1988). In the current study, the effect adenosine 
deaminase and adenosine on calcium ionophore induced histamine release were 
investigated. The results showed that there was a slight decrease o f histamine 
release induced by calcium ionophore A23187 in the concentration range of 
- adenosine deaminase, however, the decrease o f histamine release induced by 
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calc ium ionophore A23187 may due to the activities o f adenosine deaminase or 
the action o f inosine. On the other hand, relat ively constant level o f histamine 
release induced by calcium ionophore A23187 was observed in different 
concentrations o f adenosine. This observation further suggests the possible 
mechanism o f calc ium inf lux during activation o f adenosine receptor might due to 
opening calc ium channels on the plasma membrane. Previous literatures also 
suggested that the activation o f adenosine receptors i n mast cel l might be due to 
the direct action on calcium channels (MacGlashan et al., 2003; M o g u l et al., 
1993). Therefore, the possible mechanism o f adenosine enhanced rat peritoneal 
mast cells activation might due to the activation o f exist A3 adenosine receptors 
wh ich facil itate the opening o f calcium channel on the membrane and thus 
enhance calcium inf lux. Cellular calcium concentration should be measured in 
order to conf i rm this suggestion. 
When compared w i t h adenosine, inosine is a weak activator o f adenosine receptors 
(Linden, 1989). However, recent studies showed that inosine could act on 
adenosine receptor and activated mast cell degranulation. The first evidence o f the 
effects o f inosine came w i th the observation that at concentrations o f 5 to 10)J.M 
inosine stimulated RBL-2H3 rat mast cell- l ike cells degranulation by binding 
selectively to A3 receptors (Jin et aL, 1997). Subsequently, i t was reported that the 
inosine-induced enhancement o f mast-cell degranulation was lost in mice that lack 
〜 
As receptors (Ti l ley et al., 2000). Thus, recent study also observed that inosine 
appeared to b ind to A3 receptors preferentially in mast cells and enhance mast-cell 
degranulation (Hasko et aL, 2004). Therefore, the effects o f inosine mediated 
anti-IgE induced histamine release and the effects o f inosine w i th different 
adenosine receptor antagonist were studied. In the current study, it was observed 
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that inosine enhanced anti-IgE induced histamine release in a dose-dependent 
manner. There was a general increase o f percentage potentiation rather than 
inhibi t ion at the concentration range used. In order to investigate whether 
adenosine produced its effect through inosine, the effects o f inosine incubated wi th 
different adenosine receptor antagonists were performed. The results showed that 
none o f the adenosine receptor antagonists have significant enhancement or 
inhibi tory effect on inosine mediated histamine release, whi le A3 receptor 
antagonist had a tendency o f inhibitory effect on inosine mediated potentiation. 
When compared w i th the potentiation mediated by adenosine, the potentiation 
mediated by inosine did not show an inhibitory effect at low concentrations and 
reached similar maximum potentiation level 50±4% as adenosine mediated. Our 
study showed that inosine induced similar maximum potentiation level as 
adenosine mediated, this observation suggested that adenosine produced its effect 
through inosine since adenosine is metabolized to inosine. The tendency o f 
inhibitory effect by A3 receptor antagonist also suggested that inosine induced 
potentiation may through A3 adenosine receptor. The inhibitory effect induced by 
adenosine at low concentrations is most probably due to adenosine had a higher 
aff inity to A2A receptor. Adenosine binds to A2A receptor at low concentrations and 
mediated inhibitory effect on anti-IgE induced histamine release before adenosine 
is metabolized to inosine. 
5.5. Conclusion 
During mast cell activation, calcium played an important role on histamine release 
(Foreman et al, 1981; Ishizaka, 1981). In the current study similar results were 
observed that calcium was necessary for adenosine mediated potentiation of 
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anti-IgE induced rat peritoneal mast cell activation. In the calcium free buffer 
condition, the anti-IgE induced response was abolished in the calcium free buffer 
over the anti-IgE concentration range tested. Besides, the adenosine enhanced 
anti-IgE induced histamine release was also abolished in the calcium free buffer. 
Hence, adenosine may enhance the extracellular calcium inf lux associated wi th 
anti-IgE induced mast cell activation. 
Compound 48/80 and calcium ionophore A23187 were both bypassing the IgE 
receptor and calcium channel during mast cell activation (Chahdi et al., 2000; 
Pearce, 1982; Peachell et al., 1988). In the study, relatively constant o f histamine 
release induced by compound 48/80 and calcium ionophore A23187 in the 
concentration range o f adenosine tested were observed. This observation further 
confirmed that adenosine induced potentiation by facil i tating the opening o f 
calcium channel on the membrane and thus enhance extracellular calcium influx 
induced by anti-IgE. 
Moreover, recent studies showed that inosine would act on adenosine receptor and 
activated the cells through A3 adenosine receptor (Jin et al., 1997; T i l l ey et al., 
2000). Our observation showed that A3 adenosine receptor antagonists have a 
tendency o f inhibit ive effect on inosine mediated histamine release and reached 
similar maximum potentiation level as adenosine mediated. Hence, adenosine 
mediated potentiation effect through the potentiating effect induced by inosine and^ 
thus inosine mediated potentiation on anti-IgE induced histamine release through 
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